fzmd-10q_20170630.htm

0001564590-17-017201.txt : 20170810 0001564590-17-017201.hdr.sgml : 20170810 20170810142752 ACCESSION NUMBER: 0001564590-17-017201 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fuse Medical, Inc. CENTRAL INDEX KEY: 0000319016 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 591224913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-10093 FILM NUMBER: 171020980 BUSINESS ADDRESS: STREET 1: 1300 SUMMIT AVE STREET 2: SUITE 670 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817-439-7025 MAIL ADDRESS: STREET 1: 1300 SUMMIT AVE STREET 2: SUITE 670 CITY: FORT WORTH STATE: TX ZIP: 76102 FORMER COMPANY: FORMER CONFORMED NAME: GOLF ROUNDS COM INC DATE OF NAME CHANGE: 19991126 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN METALS SERVICE INC DATE OF NAME CHANGE: 19920703 10-Q 1 fzmd-10q_20170630.htm 10-Q fzmd-10q_20170630.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-10093

Fuse Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware		59-1224913
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1565 N. Central Expressway, Suite 220, Richardson, TX		75080
(Address of principal executive offices)		(Zip Code)

(817) 439-7025

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☐	(Do not check if smaller reporting company)	Smaller reporting company	☒
Emerging growth company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new of revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Indicate the number of shares outstanding of each of the registrant’s classes of Common Stock, as of the latest practicable date: As of August 7, 2017, 15,890,808 shares of the registrant’s Common Stock were outstanding.

FUSE MEDICAL, INC.

FORM 10-Q

INDEX

			PAGE
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements		F-1
	Condensed Balance Sheets at June 30, 2017 (Unaudited) and December 31, 2016		F-1
	Condensed (Unaudited) Statements of Operations for the Three-months and Six-months Ended June 30, 2017 and 2016		F-2
	Condensed (Unaudited) Statements of Changes in Stockholders' Equity for the Six-months Ended June 30, 2017		F-3
	Condensed (Unaudited) Statements of Cash Flows for the Six-months Ended June 30, 2017 and 2016		F-4
	Notes to Condensed (Unaudited) Financial Statements		F-5
Item 2.		Management's Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.		Quantitative and Qualitative Disclosures About Market Risk	7
Item 4.		Controls and Procedures	8
PART II. OTHER INFORMATION
Item 1.		Legal Proceedings	9
Item 1A.		Risk Factors	9
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds	9
Item 3.		Defaults upon Senior Securities	9
Item 4.		Mine Safety Disclosures	9
Item 5.		Other Information	9
Item 6.		Exhibits	10
Signatures			11

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

FUSE MEDICAL, INC.

CONDENSED BALANCE SHEETS

	June 30, 2017			December 31, 2016
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	445,265		$	667,475
Accounts receivable, net of allowance of $0		216,214			58,065
Inventories		18,841			25,326
Prepaid expenses and other current assets		29,346			3,528
Total current assets		709,666			754,394
Property and equipment, net		5,471			8,931
Security deposit		3,822			3,822
Total assets	$	718,959		$	767,147
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	89,174		$	83,410
Accounts payable - related parties		112,140			77,178
Accrued expenses		39,877			5,097
Note payable - related parties		150,000			150,000
Deferred rent - short term		664			160
Total current liabilities		391,855			315,845
Deferred rent - long term		230			687
Total liabilities		392,085			316,532
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock, $0.01 par value; 100,000,000 shares authorized, 15,890,808 shares issued and outstanding		158,908			158,908
Additional paid-in capital		3,192,686			3,192,686
Accumulated deficit		(3,024,720	)		(2,900,979	)
Total stockholders' equity		326,874			450,615
Total liabilities and stockholders' equity	$	718,959		$	767,147

The accompanying notes are an integral part of these condensed financial statements.

F-1

FUSE MEDICAL, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three-months Ended June 30, 2017			For the Three-months Ended June 30, 2016			For the Six- months Ended June 30, 2017			For the Six- months Ended June 30, 2016
Revenues	$	334,672		$	120,643		$	482,829		$	313,586
Cost of revenues (primarily from related party, see note 8)		114,992			20,837			163,302			102,118
Gross profit		219,680			99,806			319,527			211,468
Operating expenses:
General, administrative and other		219,286			182,938			470,028			411,515
Loss on disposal of property and equipment		-			-			307			1,580
Depreciation		996			3,522			2,853			7,164
Total operating expenses		220,282			186,460			473,188			420,259
Operating loss		(602	)		(86,654	)		(153,661	)		(208,791	)

Interest expense		(6,731	)		(1,750	)		(13,388	)		(3,500	)
Extinguishment of debt		-			-			43,308			-

Net loss	$	(7,333	)	$	(88,404	)	$	(123,741	)	$	(212,291	)
Net loss per common share - basic and diluted	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.03	)
Weighted average number of common shares outstanding - basic and diluted		15,890,808			6,890,808			15,890,808			6,890,808

The accompanying notes are an integral part of these condensed financial statements.

F-2

FUSE MEDICAL, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(Unaudited)

	Common Stock				Additional Paid-In		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, December 31, 2016		15,890,808	$	158,908	$	3,192,686	$	(2,900,979	)	$	450,615
Net loss		-		-		-		(123,741	)		(123,741	)
Balance, June 30, 2017		15,890,808	$	158,908	$	3,192,686	$	(3,024,720	)	$	326,874

The accompanying notes are an integral part of these condensed financial statements.

F-3

FUSE MEDICAL, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Six- months Ended June 30, 2017			For the Six- months Ended June 30, 2016
Cash flows from operating activities
Net loss	$	(123,741	)	$	(212,291	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation		2,853			7,164
Loss on disposal of property and equipment		307			1,580
Extinguishment of debt		(43,308	)		-
Changes in operating assets and liabilities
Accounts receivable		(158,149	)		263,173
Inventories		6,485			55,730
Prepaid expenses and other receivables		(25,818	)		9,257
Accounts payable		49,072			(89,858	)
Accounts payable - related parties		34,962			(14,573	)
Accrued expenses		34,781			72
Deferred revenues		-			91,534
Deferred rent		46			550
Net cash (used in) provided by operating activities		(222,510	)		112,338
Cash flows from investing activities
Proceeds from the disposal of property and equipment		300			300
Net cash provided by investing activities		300			300
Net (decrease) increase in cash and cash equivalents		(222,210	)		112,638
Cash and cash equivalents - beginning of period		667,475			8,157
Cash and cash equivalents - end of period	$	445,265		$	120,795
Supplemental disclosure of cash flow information:
Interest Paid	$	-		$	3,500

The accompanying notes are an integral part of these condensed financial statements.

F-4

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

Note 1. Nature of Operations

Overview

The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Delaware corporation. Effective May 28, 2014, the Company amended its certificate of incorporation to change its name from “GolfRounds.com, Inc.” to “Fuse Medical, Inc.” (the “Company”). Then, also on May 28, 2014, the Company merged with and into Fuse Medical, LLC, with Fuse Medical, LLC surviving as a wholly owned subsidiary of Fuse Medical, Inc (“Legacy Fuse”). The transaction was accounted for as a reverse merger with Fuse Medical, Inc. deemed the legal acquirer, and Fuse Medical, LLC deemed the accounting acquirer. During 2015, Certificates of Termination were filed for Fuse Medical, LLC and its two subsidiaries.

On December 19, 2016 (the “Closing Date”), the Company entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), and Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg (“RMI” and, together with NC 143, the “Investors”), pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. The closing of the Purchase Agreement resulted in a change in control of the Company whereby the Investors acquired a majority interest in the Company. Effective as of the Closing Date, Mark W. Brooks became the Chairman of the Board of Directors and Christopher C. Reeg became the Chief Executive Officer of the Company.

The Company distributes a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, and full spinal implants for trauma, degenerative disc disease and deformity indications (“Orthopedic Implants”). The Company also supports its broad portfolio of Orthopedic Implants with human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). The Company’s principal supplier is CPM Medical Consultants, LLC (“CPM”) a company owned and controlled by the Company’s Chairman of the Board of Directors. The Company strives to provide cost savings and quality products to its customers, which include hospitals and medical facilities.

Basis of Presentation

The interim condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading.

The condensed balance sheet information as of December 31, 2016, was derived from the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017 (“2016 Annual Report”). These condensed financial statements should be read in conjunction with the 2016 Annual Report.

The results of operations for the three and six-months ended June 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period.

F-5

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

Going Concern

The accompanying condensed financial statements have been prepared as if the Company will continue as a going concern. For the six-month period ended June 30, 2017, the Company had net cash used in operations of $222,510, of which $123,741 represented a net loss. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the ability of the Company’s management to successfully execute its restructuring and rebranding strategies and to achieve a level of profitability. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2016 audited financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.

The Company’s management expects to fund its future business development activities and its working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time adequate funds are provided by operations. There can be no assurance that the Company’s financing efforts will be successful, or if the Company’s management will be able to achieve profitable operations. Additional financing, may include restrictions on the Company’s operations in the case of debt, or cause dilution for the Company’s stockholders in the case of equity financing.

The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2. Significant Accounting Policies

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying condensed financial statements include the allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards.

Earnings (Loss) Per Share

The Company’s computation of Earnings (loss) Per Share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that would have occurred if securities or other contracts to issue common shares (e.g., warrants and options) had been exercised or converted into common shares at the beginning of the period, or issuance date, if later, and had shared in the net income (loss) of the Company. Diluted EPS is computed using the treasury stock method, which assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common shares at the average market price during the period. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

As of June 30, 2017, and 2016, common stock equivalents included options to purchase 1,304,788 and 609,576 common shares, respectively. These instruments are not considered in the calculation of diluted loss per share because the effect would be anti-dilutive.

Fair Value Measurements

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy:

F-6

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets,

Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities, and

Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates.

Reclassifications

Certain amounts in the accompanying condensed financial statements as of June 30, 2016, and for the three-months and six-months then ended, have been reclassified to conform to the June 30, 2017 condensed financial statements for the three-months and six-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively.

Cash and Cash Equivalents

The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at June 30, 2017 and 2016. The Company maintains its cash in financial institution deposit accounts that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through June 30, 2017. As of June 30, 2017, and December 31, 2016, there were deposits of $206,693 and $421,636, respectively, greater than federally insured limits.

Accounts Receivable and Allowance for Doubtful Accounts Receivable

Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts.

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit.

Income Taxes

The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income.

The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of June 30, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to

F-7

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

Revenue Recognition

The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs).

Stock-Based Compensation

Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro-rata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures.

F-8

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

All other ASUs issued and not yet effective for the six-months ended June 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.

Note 3. Property and Equipment

Property and equipment consisted of the following at June 30, 2017 and December 31, 2016:

	June 30, 2017			December 31, 2016
Computer equipment	$	-		$	29,290
Furniture and fixtures		5,047			6,347
Leasehold improvements		6,728			6,728
Office equipment		1,580			1,580
		13,355			43,945
Less: accumulated depreciation		(7,884	)		(35,014	)
Property and equipment, net	$	5,471		$	8,931

Depreciation expense for the three-months ended June 30, 2017 and 2016 was $996 and $3,522, respectively. Depreciation expense for the six-months ended June 30, 2017 and 2016 was $2,853 and $7,164, respectively. During the six months ended June 30, 2017 the Company disposed of furniture and fixtures with a net book value of $607 for proceeds of $300, resulting in a loss of $307 on disposal of property and equipment.

Note 4. Notes Payable – Related Parties

During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. This resulted in a beneficial conversion feature in the aggregate amount of $117,500, which was treated as a discount to each of the promissory notes and amortized over the term of each respective promissory note, maturing on December 31, 2016, the date in which the beneficial conversion feature was fully amortized.

During the three-months ended June 30, 2017 and 2016, interest expense of $6,731 and $1,750, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. During the six-months ended June 30, 2017 and 2016, interest expense of $13,388 and $3,500, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. As of June 30, 2017, and December 31, 2016, accrued interest payable was $18,485 and $5,096, respectively, which is included in accrued expenses on the accompanying condensed balance sheets.

F-9

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

Note 5. Commitments and Contingencies

Legal Matters

On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 2014-03355, against Legacy Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc. (the “Defendants”). On April 21, 2014, the complaint was dismissed for “want of prosecution.” On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff, as more fully described in “Legal Matters” included in Note 6 in our 2016 Annual Report, which is herein incorporated by reference. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set.

The Company’s management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect our interests.

Accounts Payable

During the six-months ended June 30, 2017, the Company recorded a gain of $43,308 on extinguishment of long-aged outstanding payables owed to a former law firm for $32,052 and liabilities aggregating $11,256 owed to the Company’s beneficial owners for services provided to the Company and is reflected within extinguishment of debt on the accompanying condensed statements of operations. The Company’s management believes if these items were contested, the probable outcome would be favorable primarily due to statute of limitations.

Note 6. Stockholders' Equity

Stock Options

Stock Incentive Plans

The Company has a share-based compensation plan which provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors; the 2017 Equity Incentive Plan of Fuse Medical, Inc. (the “2017 Plan”), which was adopted by the Company’s Board of Directors on April 5, 2017. The awards are subject to a vesting schedule as set forth in individual agreements. No equity awards have been issued pursuant to the 2017 Plan.

The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the six-months ended June 30, 2017 is presented below:

	No. of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance outstanding at December 31, 2016		1,304,788	$	0.22		4.3	$	35,000
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Balance outstanding at June 30, 2017		1,304,788	$	0.22		3.8	$	183,000
Exercisable at June 30, 2017		1,304,788	$	0.22		3.8	$	183,000

F-10

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

Note 7. Concentrations

Concentration of Revenues, Accounts Receivable and Suppliers

For the three-months and six-months ended June 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:

	For the Three-months Ended June 30, 2017			For the Three-months Ended June 30, 2016			For the Six-months Ended June 30, 2017			For the Six-months Ended June 30, 2016
Customer 1		45.8	%		0.0	%		38.2	%		0.0	%
Customer 2		22.2	%		0.0	%		23.5	%		0.0	%
Customer 3		17.9	%		0.0	%		24.6	%		0.0	%
Customer 4		13.1	%		0.0	%		9.1	%		0.0	%
Totals		99.0	%		0.0	%		95.4	%		0.0	%

At June 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:

	June 30, 2017			December 31, 2016
Customer 1		43.3	%		0.0	%
Customer 2		20.3	%		0.0	%
Customer 3		20.1	%		10.3	%
Customer 4		14.8	%		0.0	%
Totals		98.5	%		10.3	%

The Company’s principal supplier is CPM and provided 10% or greater of the Company’s goods purchased for the periods presented below:

For the Three-months Ended

June 30, 2017

For the Three-months Ended

June 30, 2016

For the Six-months Ended

June 30, 2017

For the Six-months Ended

June 30, 2016

Supplier 1

100.0

32.7

98.1

15.3

Totals

100.0

32.7

98.1

15.3

Note 8. Related Party Transactions

The Company entered into a distributor agreement with CPM effective August 2, 2012, pursuant to which the Company acts as a non-exclusive distributor of certain amniotic membrane products. The term of the agreement is one year and renews on each annual anniversary date for successive one-year terms unless it is terminated in writing by either party. Effective January 1, 2017, this agreement was amended to expand and include Orthopedic Implants and a broader assortment of Biologics. (See Note 1)

During the three-months ended June 30, 2017 and 2016 the Company sold $112,140 and $3,940, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the six-months ended June 30, 2017 and 2016 the Company sold $157,582 and $13,000, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations.

During the three-months ended June 30, 2017 and 2016 the Company purchased $112,665 and $13,200, respectively, of its products from CPM. During the six-months ended June 30, 2017 and 2016 the Company purchased $158,107 and $13,200, respectively, of its products from CPM. The balance due to CPM at June 30, 2017 and December 31, 2016 was $112,140 and $77,178, respectively, and are reflected within accounts payable – related parties on the accompanying condensed balance sheets.

F-11

FUSE MEDICAL, INC.

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

FOR THE THREE AND SIX-MONTHS ENDED JUNE 30, 2017
(Unaudited)

During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. The balance of the notes payable at June 30, 2017 and December 31, 2016 was $150,000.

On December 19, 2016, the Company entered into the Purchase Agreement by and among the Company, NC 143, and RMI, pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. (See Note 1)

During the three-months and six-months ended June 30, 2017, CPM provided shared services for back-office functions such as accounting, finance, supply chain management, and sales support. In addition, the Company’s Chief Executive Officer and Interim Chief Financial Officer provided services at no charge to the Company. The financial statements do not reflect an estimate of fair value of these services.

Effective January 1, 2017 the Company engaged AmBio Staffing, LLC, a Texas licensed professional employment organization to provide payroll processing, employee benefit administration, and related human capital services. AmBio Staffing, LLC is owned and controlled by the Company’s Chairman of the Board of Directors. The balance due to AmBio Staffing, LLC at June 30, 2017 and December 31, 2016 was $8,660 and $0, respectively, and is reflected within accounts payable on the accompanying condensed balance sheets. For the three-months and six-months ended June 30, 2017, $2,757 and $6,877 of fees were paid to AmBio Staffing, LLC for such services, respectively and are reflected within general, administrative and other expenses on the accompanying condensed statements of operations.

Note 9. Subsequent Events

On July 17, 2017, the Company entered into an assignment of sublease and consent, dated July 17, 2017 terminating all obligations of the Company under its assigned office sublease at 1300 Summit Avenue, Suite 670, Fort Worth, Texas 76102.

On July 19, 2017, the Company entered into a commercial property lease agreement for its new office space located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080, dated to be effective July 14, 2017, by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s Chairman of the Board of Directors. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.

F-12

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Explanatory Note

As used in this report on Form 10-Q, “we”, “us”, “our”, and the “Company” refer to Fuse Medical, Inc.

Overview

We are an emerging national medical device distributor providing a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, full spinal implants for trauma, degenerative disc disease and deformity indications, (“Orthopedic Implants”), and human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”) to support orthopedic surgeries and wound care. Our Biologics include:

•

Osteo Biologics – Cellular bone allografts, synthetics.

•

Tendon and Tissue – Ligaments, tendons, dermal graft.

•

Regenerative tissues – Amniotic membrane (dry), amniotic membrane (injectable), and amniotic fluids (frozen).

•

Autologous products – Platelet Rich Plasma, and Bone Marrow Aspirate concentration systems.

Medical device companies such as ours typically experience seasonality between the first two quarters compared to the last two quarters of the year. We believe this is in part the result of patient annual healthcare deductibles being met during the last two quarters of the calendar year compared to the first two quarters of the calendar year.

As more fully described in our Annual Report on Form 10-K for the year ended December 31, 2016, as filed on March 20, 2017 (the “2016 Annual Report”), during December 2016 the change in control over a majority of our issued and outstanding voting common stock resulted in new executive leadership.

Our new executive leadership has the following strategic objectives:

•

Scalable cost effective infrastructure.

•

Broaden and expand product offerings.

•

Migrate sales model from fixed cost to variable cost.

•

Acquire strategic independent distributors.

During the six-months ended June 30, 2017, we have successfully executed the following milestones:

•

Expanded product offerings from two manufacturers to over forty.

•

Effective January 1, 2017 all supply-chain, finance, sales support and other related functions were outsourced to a shared service platform providing scalability and strengthening internal controls.

•

Payroll and human capital functions were outsourced to a licensed Texas professional employment organization owned and controlled by our Chairman of the Board of Directors.

•

Legacy sales management was replaced with arrangements with established independent contractors who contribute existing books of business with strong revenue, and in-depth industry experience.

•

Fixed costs contracts with third-party service providers have been renegotiated for more favorable terms or terminated.

•

Conducted formalized initiatives:

To identify synergistic acquisition targets;

Vertical supply chain integration opportunities, and

Strategic high value new vendor relationships.

We continue to believe our comprehensive selection of Orthopedic Implants and Biologics products will prove instrumental in our ability to acquire new customers and increase revenues and profitability as demonstrated by our three months-ended March 31, 2017 and June 30, 2017 results of operations over the prior year. We expect to offer incentives to key distributors, executive leadership and key employees as we continue to expand our strategic partnerships and network arrangements.

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the U.S., (or “GAAP”), requires our management to make judgments, assumptions and estimates that affect the amounts of revenue, expenses, income, assets and liabilities, reported in our condensed financial statements and accompanying notes. Understanding our accounting policies and the extent to which our management uses judgment, assumptions and estimates in applying these policies is integral to understanding our financial statements.

We describe our most significant accounting policies in Note 2, “Significant Accounting Policies” of our condensed notes to the financial statements beginning on page F-1 and found elsewhere in this report, and in our 2016 Annual Report. These policies are considered critical because they may result in fluctuations in our reported results from period to period due to the significant judgments, estimates and assumptions about highly complex and inherently uncertain matters and because the use of different judgments, assumptions or estimates could have a material impact on our financial condition or results of operations. We evaluate our critical accounting estimates and judgments required by our policies on an ongoing basis and update them as appropriate based on changing conditions.

There have been no material changes to our critical accounting policies during the period covered by this report.

Recent Accounting Pronouncements

See Note 2 to the condensed financial statements included in this report for management’s discussion of recent accounting pronouncements.

Results of Operations

The following table sets forth certain financial information from our condensed statements of operations along with a percentage of net revenue and should be read in conjunction with the condensed financial statements and related notes included in this report.

	For the Three-months Ended June 30, 2017			(%)		For the Three-months Ended June 30, 2016			(%)		For the Six-months Ended June 30, 2017			(%)		For the Six-months Ended June 30, 2016			(%)
Revenues	$	334,672			100%	$	120,643			100%	$	482,829			100%	$	313,586			100%
Cost of revenues		114,992			34%		20,837			17%		163,302			34%		102,118			33%
Gross profit		219,680			66%		99,806			83%		319,527			66%		211,468			67%
Operating expenses:
General, administrative and other		219,286			66%		182,938			152%		470,028			97%		411,515			131%
Loss on disposal of property and equipment		-			0%		-			0%		307			0%		1,580			1%
Depreciation		996			0%		3,522			3%		2,853			1%		7,164			2%
Total operating expenses		220,282			66%		186,460			155%		473,188			98%		420,259			134%
Operating loss		(602	)		0%		(86,654	)		-72%		(153,661	)		-32%		(208,791	)		-67%

Interest expense		(6,731	)		-2%		(1,750	)		-1%		(13,388	)		-3%		(3,500	)		-1%
Extinguishment of debt		-			0%		-			0%		43,308			9%		-			0%

Net loss	$	(7,333	)		-2%	$	(88,404	)		-73%	$	(123,741	)		-26%	$	(212,291	)		-68%

Three-months Ended June 30, 2017 Compared to Three-months Ended June 30, 2016

Revenues

For the three-months ended June 30, 2017, revenues were $334,672 compared to $120,643 for the three-months ended June 30, 2016, an increase of $214,029, or approximately 177%. The increase in revenues is primarily a result of an approximate 36% increase in case count volume and an approximate 141% increase in average price per case. We gained four new customers, offset, in part, by two customers becoming inactive.

Cost of Revenues

For the three-months ended June 30, 2017, our cost of revenues was $114,992, compared to $20,837 for the three-months ended June 30, 2016, representing an increase of $94,155, or approximately 452%. The increase in cost of revenues is primarily attributable to an approximate 36% increase in revenue case volume and shift to Orthopedic Implants case volume which carry higher average cost.

Gross Profit

For the three-months ended June 30, 2017, we generated a gross profit of $219,680, compared to $99,806 for the three-months ended June 30, 2016, an increase of $119,874, or approximately 120%. As a percentage of revenue, gross profit was approximately 66% and 83% for the three-months ended June 30, 2017 and 2016, respectively. The decline in percentage of revenues is approximately 17%

and is primarily a result of our strategy to increase Orthopedic Implant revenue. For the three-months ended June 30, 2017 and 2016, Orthopedic Implants represented 72% and 6% of revenues, respectively.

General, Administrative and Other Expenses

For the three-months ended June 30, 2017, general, administrative and other operating expenses increased to $219,286 from $182,938 for the three-months ended June 30, 2016, representing an increase of $36,348, or approximately 20%. As a percentage of revenue, general, administrative and other operating expenses were approximately 66% and 152% for the three-months ended June 30, 2017 and 2016, respectively. The decrease as a percentage of revenues is approximately 86% and is primarily the result of a decrease of approximately 65% for payroll and benefit expense, a decrease of approximately 21% in professional fees, a 17% reduction in other corporate expense, approximately 5% of savings from our exit of sponsorship programs, offset, in part, by an approximate 19% increase in legal and valuation study costs relating to our corporate restructuring and rebranding strategies, and an approximately 3% increase in commission expense.

Depreciation Expense

For the three-months ended June 30, 2017, depreciation expense decreased to $996 from $3,522 for the three-months ended June 30, 2016, representing a decrease of $2,526 or approximately 72%. The decrease is primarily related to a reduction in fixed assets.

Interest Expense

For the three-months ended June 30, 2017, interest expense increased to $6,731 from $1,750 for the three-months ended June 30, 2016, representing an increase of $4,981, or approximately 285%. The increase is primarily related to note payables – related party originating July 15, August 23, and October 19, 2016.

Net Loss

For the three-months ended June 30, 2017, we had a net loss of $7,333 compared to a net loss of $88,404 for the three-months ended June 30, 2016, representing improved profitability by $81,071 or approximately 92%. This increase in profitability as a percentage of revenues was approximately 71% and is primarily a result of a reduction of approximately 86% in general, administrative and other operating expenses and a reduction in depreciation expense of approximately 3%, offset, in part, by approximately a 17% reduction in gross profit and an approximate 1% increase in interest expense.

Six-months Ended June 30, 2017 Compared to Six-months Ended June 30, 2016

Revenues

For the six-months ended June 30, 2017, revenues were $482,829, compared to $313,586 for the six-months ended June 30, 2016, an increase of $169,243, or approximately 54%. The increase in revenues is primarily a result of an approximate 11% increase in case count volume and an approximate 43% increase in average price per case. We gained five new customers, offset, in part, by six customers becoming inactive.

Cost of Revenues

For the six-months ended June 30, 2017, our cost of revenues was $163,302, compared to $102,118 for the six-months ended June 30, 2016, representing an increase of $61,184, or approximately 60%. The increase in cost of revenues is primarily attributable to an approximate 11% increase in revenue case volume and a product mix shift to increased Orthopedic Implants case volume, which carry higher average cost.

Gross Profit

For the six-months ended June 30, 2017, we generated a gross profit of $319,527, compared to $211,468 for the six-months ended June 30, 2016, an increase of $108,059, or approximately 51%. As a percentage of revenue, gross profit was approximately 66% and 67% for the six-months ended June 30, 2017 and 2016, respectively. The decline in percentage of revenues is approximately 1% and is primarily a result of our strategy to increase Orthopedic Implants revenue. For the three-months ended June 30, 2017 and 2016, Orthopedic Implants represented 75% and 5% of revenues, respectively.

General, Administrative and Other Expenses

For the six-months ended June 30, 2017, general, administrative and other operating expenses increased to $470,028 from $411,515 for the six-months ended June 30, 2016, representing an increase of $58,513, or approximately 14%. As a percentage of revenue, general, administrative and other was approximately 97% and 131% for the six-months ended June 30, 2017 and 2016, respectively. This decrease as a percentage of revenues is approximately 34% and is primarily the result of a reduction of approximately 36% for payroll and benefits, approximately 9% for professional fees, approximately 8% for other corporate fixed costs, approximately 4% of savings from our exit of sponsorship programs, offset, in part, by an approximately 23% increase in legal and valuation study costs relating to our corporate restructuring and rebranding initiatives.

Depreciation Expense

For the six-months ended June 30, 2017, depreciation expense decreased to $2,853 from $7,164 for the six-months ended June 30, 2016, representing a decrease of $4,311 or approximately 60%. The decrease is primarily related to a reduction in fixed assets.

Interest Expense

For the six-months ended June 30, 2017, interest expense increased to $13,388 from $3,500 for the six-months ended June 30, 2016, representing an increase of $9,888, or approximately 283%. The increase is primarily related to note payables – related party originating July 15, August 23, and October 19, 2016.

Extinguishment of Debt

For the six-months ended June 30, 2017 we recorded a $43,308 on extinguishment of debt, primarily related to long-aged outstanding payables owed to a former law firm for $32,052 and liabilities aggregating $11,256 owed to the Company’s beneficial owners for services provided to the Company.

Net Loss

For the six-months ended June 30, 2017, we generated a net loss of $123,741 compared to a net loss of $212,291 for the six-months ended June 30, 2016. The decrease is primarily due to reduced general, administrative and other costs, and extinguishment of debt, offset by increased interest expense as a percentage to revenue.

Liquidity and Capital Resources

A summary of our cash flows is as follows:

	Six Months Ended June 30,
	2017			2016
Net cash (used in) provided by operating activities	$	(222,510	)	$	112,338
Net cash provided by investing activities		300			300
Net (decrease) increase in cash and cash equivalents	$	(222,210	)	$	112,638

Net Cash (Used in) Provided by Operating Activities

Net cash used in operating activities during the six-months ended June 30, 2017 resulted primarily from a net loss of $123,741, a $158,149 increase in accounts receivable, a $25,818 increase in prepaid expenses and other receivables, $40,148 of adjustments in depreciation expense and other non-cash items, net, offset in part, by $49,072 increase in accounts payable, $34,962 increase in accounts payable-related parties, $34,781 increase in accrued expenses, $6,485 reduction in inventories, and $46 increase in deferred rent.

Net Cash Provided by Investing Activities

Net cash provided by investing activities for the six-months ended June 30, 2017 resulted cash proceeds from the disposal of property and equipment of $300.

Net Cash Provided by Financing Activities

There were no cash financing activities during the six-months ended June 30, 2017.

Liquidity

At June 30, 2017, we had working capital of $317,811, including $445,265 in cash and cash equivalents. As of August 7, 2017, we had approximately $460,000 in available cash. Our cash is concentrated in a large financial institution. We believe that our current cash balance, along with anticipated cash generated by operations, an expanded network of independent distributors, and execution of our initiatives will be enough to sustain operations through June 30, 2018.

The accompanying condensed financial statements have been prepared as if we will continue as a going concern. For the six-month period ended June 30, 2017, we had net cash used in operations of $222,510, of which $123,741 represented a net loss. In view of these matters, our ability to continue as a going concern is dependent upon our ability to successfully continue executing our restructuring and rebranding strategies and to achieve a level of profitability. We expect to fund our future business development activities and our working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time that funds are provided by operations. Our independent registered public accounting firm, in its report on our 2016 audited financial statements, has raised substantial doubt about our ability to continue as a going concern. There can be no assurance that our financing efforts will be successful, or if our management will be able to achieve profitable operations. Additional financing, may include undue restrictions on our operations in the case of debt, or cause substantial dilution for our stockholders in the case of equity financing.

The estimated costs of operations while we work to increase our revenues is substantially greater than the amount of funds we have on hand. Our existence is dependent upon our ability to execute our restructuring and rebranding strategies and have accessibility to adequate funding as required. There can be no assurance that our efforts will result in profitable operations or provide resolution of our liquidity challenges. See Risk Factors, Item 1A, in our 2016 Annual Report.

In our 2016 Annual Report, our independent registered public accounting firm included an emphasis-of-matter paragraph with respect to our financial statements concerning our assumption that we will continue as a going concern.

Capital Expenditures

For the six-months ended June 30, 2017, we had no material capital expenditures. We have no material commitments for capital expenditures as of June 30, 2017. As we begin to execute on growth strategies, we may invest up to $100,000 in capital expenditures over the next 12 months. These capital expenditures will be allocated across business development initiatives, including investment in inventories and scalable infrastructure.

Cautionary Note Regarding Forward-Looking Statements

This report includes forward-looking statements including statements regarding liquidity.

The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

The results anticipated by any or all of these forward-looking statements might not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include the condition of the capital markets, particularly for smaller companies, willingness of doctors and facilities to purchase the products that we sell and regulatory issues adversely affecting our margins, insurance companies denying reimbursement to facilities who use the products that we sell and/or our ability to sell products. We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of new information, future events or otherwise.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Based upon the evaluation required by Section 13a-13(b) of the Securities Exchange Act of 1934, as amended, our Chief Executive Officer and Chief Financial Officer, with the participation of our Board of Directors, have deemed disclosure controls and procedures, as of June 30, 2017, significantly improved since December 31, 2016.

Our management is responsible for establishing and maintaining adequate internal controls over our financial reporting. With the new executive leadership team, including the Chief Executive Officer and the Chief Financial Officer, and the significant required restructuring and rebranding efforts deemed necessary by our Board of Directors, our management was unable to complete their full assessment regarding the establishment and maintenance of adequate internal controls over our financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework. Due to the lack of such analysis, management believes internal controls over financial reporting were not effective as of that date. Our Board of Directors, Chief Executive Officer, and Chief Financial Officer have committed to engaging an independent third party consulting firm during the third quarter of 2017 to assist in establishing a sustainable framework and processes to ensure adequate internal controls over financial reporting.

Changes in Internal Controls Over Financial Reporting

During the six-months ended June 30, 2017, we out-sourced our supply chain management, finance, sales support, and other related functions, including payroll processing, employee benefit administration, and related human capital services to companies owned and controlled by our Chairman of the Board of Directors. We believe these arrangements have significantly improved internal controls over financial reporting and have provided us scalability for anticipated growth and expansion, while driving down fixed costs per transaction.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 2014-03355, against Legacy Fuse (See Note 1, “Nature of Operations and liquidity” of our interim condensed notes to the financial statements beginning on page F-1 and found elsewhere in this report), Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc. (the “Defendants”). On April 21, 2014, the complaint was dismissed for “want of prosecution.” On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff, as more fully described in “Legal Matters” included in Note 6 in our 2016 Annual Report, which is herein incorporated by reference. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set.

Our management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect our interests.

ITEM 1A. RISK FACTORS.

As a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

On March 31, 2017, David A. Hexter resigned as our Chief Financial Officer and Principal Accounting Officer as well as from all other positons held with us and our subsidiaries. Our Board of Directors appointed William E. McLaughlin, III, to serve as interim Chief Financial Officer and Principal Accounting Officer until such time we can economically sustain a full-time position of such caliber. Mr. McLaughlin currently serves as a member of the Board of Directors and is Chairman of the Audit Committee.

On April 3, 2017, Robert H. Donehew and Christopher C. Pratt, D.O. each resigned as members of our Board of Directors.

On April 5, 2017, our Board of Directors approved the 2017 Equity Incentive Plan of the Company, subject to approval by our shareholders. The 2017 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, and other stock-based awards.

Each of the above events was reported in our Current Report on Form 8-K, filed on April 6, 2017.

On July 19, 2017, we entered into that certain Commercial Property Lease Agreement, dated to be effective July 14, 2017 by and between the Company and 1565 North Central Expressway, LP—an entity controlled by our Chairman of the Board of Directors. The Lease provides that we will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.

On July 17, 2017, we entered into that certain Assignment of Sublease and Consent, dated July 17, 2017 by and between (i) PBIII-SOP, LP, (ii) PHILLIP GALYEN, PC, d/b/a Bailey & Galyen, (iii) the Company, and (iv) LawConnect, Inc. d/b/a GetLegal.com. Pursuant to the Assignment Agreement, we assigned to LawConnect all of our rights, title, and interest in that certain Sublease Agreement, dated September 1, 2015, by and between us and Galyen.

On July 13, 2017, our Board of Directors appointed “Ricky” Raj S. Kalra, M.D. to serve as a member of the Board.

Dr. Kalra is a spine fellowship-trained neurosurgeon in Dallas, Texas. He attended Rice University where he received a degree in economics. He also attended London School of Economics as a Hansard Scholar. Dr. Kalra worked at Merrill Lynch in their investment banking buisness after his undergraduate education. He then attended Washington University School of Medicine in Saint Louis and completed his neurosurgery residency at the University of Utah. As part of his spine fellowship, Dr. Kalra trained in Germany under Dr. Rudolf Beisse. Dr. Kalra has published more than twenty scientific articles and book chapters and has received the Preuss award by the Congress of Neurological Surgeons for his research in brain tumors. Dr. Kalra was appointed to our Board of Directors for his financial acumen as well as experience in the industry.

The Company and Dr. Kalra are parties to an Independent Contractor Agreement, dated July 1, 2017, whereby we agreed to pay Dr. Kalra $10,000 in return for the provision of his analysis and advice on certain strategic matters. The entire Consulting Fee was paid to Dr. Kalra prior to his appointment to our Board of Directors.

Each of the above events was reported in our Current Report on Form 8-K, filed on July 19, 2017.

On August 1, 2017, the Board of Directors (the “Board”) of the Company appointed Renato V. Bosita Jr., M.D., M.B.A. to serve as a member of the Board.

Dr. Bosita is a spine fellowship-trained orthopedic spine surgeon in Plano, Texas. He attended Stanford University where he received a degree in biological sciences. He then attended the University of Chicago Pritzker School of Medicine and completed his residency in orthopedic surgery at Loyola University Medical Center. While a resident at Loyola University Medical Center, Dr. Bosita earned a Masters of Business Administration degree from the University of Northwestern J.L. Kellogg Graduate School of Management. Dr. Bosita completed his spine fellowship at the University Hospitals of Cleveland. Dr. Bosita currently practices as a spine surgeon at the Texas Back Institute, Plano, Texas. Additionally, Dr. Bosita is the Chairman of the Board of Managers for Presbyterian Hospital of Rockwall and is a member of the finance committee. Dr. Bosita was appointed to our Board of Directors for his experience in the healthcare industry and business acumen.

Each of the above events was reported in our Current Report on Form 8-K, filed on August 3, 2017.

ITEM 6. EXHIBITS.

See the exhibits listed in the accompanying “Exhibit Index”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	FUSE MEDICAL, INC.

Date: August 10, 2017	By:	/s/ Christopher C. Reeg
		Christopher C. Reeg
		Chief Executive Officer and Director (Principal Executive Officer)

Date: August 10, 2017

By:

/s/ William E. McLaughlin, III

William E. McLaughlin, III

Interim Chief Financial Officer and Director

(Principal Accounting Officer)

EXHIBIT INDEX

Exhibit No.		Description


3.1		Amended and Restated Certificate of Incorporation of the Company (filed as Exhibit 3.1 to the Company’s Form 8-K, filed on September 15, 2014, and incorporated herein by reference).

3.2		Amendment to the Amended and Restated Certificate of Incorporation of the Company (filed as Annex A to the Company’s Information Statement, filed on December 4, 2015, and incorporated herein by reference).


3.3		Bylaws (filed as Exhibit 3.2 to the Company’s Current Report Form 8-K, filed on May 29, 2014, and incorporated herein by reference).


3.4		Certificate of Merger, as filed with the Secretary of State of the State of Delaware on May 28, 2014 (filed as Exhibit 3.3 to the Company’s Form 8-K filed on May 29, 2014, and incorporated herein by reference).


3.5		Amendment No. 1 to the Bylaws (filed as Exhibit 3.1 to the Company’s Form 8-K, filed on December 19, 2016, and incorporated herein by reference).

4.1		2017 Equity Incentive Plan of Fuse Medical, Inc. dated April 5, 2017 (filed as Exhibit 99.2 to the Company’s Form 8-K filed April 6, 2017, and incorporated herein by reference).

10.1		Settlement Agreement, General Release and Covenant Not to Sue, dated to be effective March 31, 2017 by and between Fuse Medical, Inc. and David A. Hexter (filed as Exhibit 10.1 to the Company’s Form 8-K filed April 6, 2017, and incorporated herein by reference).

10.2		Commercial Property Lease Agreement dated July 19, 2017 by and between Fuse Medical, Inc. and 1565 North Central Expressway, LP (filed as Exhibit 10.1 to the Company’s Form 8-K, filed on July 19, 2017, and incorporated herein by reference).

10.3		Assignment of Sublease and Consent, dated July 17, 2017, by and between (i) PBIII-SOP, LP, (ii) PHILLIP GALYEN, PC, d/b/a Bailey & Galyen, (iii) Fuse Medical, Inc., and (iv) LawConnect, Inc. d/b/a GetLegal.com (filed as Exhibit 10.2 to the Company’s Form 8-K, filed on July 19, 2017, and incorporated herein by reference).

10.4		Sublease Agreement dated September 1, 2015, by and between Fuse Medical, Inc. and PHILLIP GALYEN, PC, d/b/a Bailey & Galyen (filed as Exhibit 10.3 to the Company’s Form 8-K, filed on July 19, 2017, and incorporated herein by reference).

31.1*		Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


31.2*		Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.


32.1**		Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


101.INS *		XBRL Instance Document

101.SCH *		XBRL Taxonomy Extension Schema Document


101.CAL *		XBRL Taxonomy Extension Calculation Linkbase Document


101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document


101.LAB *		XBRL Taxonomy Extension Label Linkbase Document


101.PRE *		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

**	Furnished herewith

EX-31.1 2 fzmd-ex311_6.htm EX-31.1 fzmd-ex311_6.htm

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Christopher C. Reeg, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Fuse Medical, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 10, 2017	By:	/s/ Christopher C. Reeg
		Christopher C. Reeg
		Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 fzmd-ex312_8.htm EX-31.2 fzmd-ex312_8.htm

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, William E. McLaughlin, III, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Fuse Medical, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 10, 2017	By:	/s/ William E. McLaughlin, III
		William E. McLaughlin, III
		Interim Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 fzmd-ex321_7.htm EX-32.1 fzmd-ex321_7.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Fuse Medical, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, Christopher C. Reeg, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 10, 2017	By:	/s/ Christopher C. Reeg
		Christopher C. Reeg
		Chief Executive Officer (Principal Executive Officer)

In connection with the quarterly report of Fuse Medical, Inc. (the "Company") on Form 10-Q for the quarter ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof, I, William E. McLaughlin, III, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 10, 2017	By:	/s/ William E. McLaughlin, III
		William E. McLaughlin, III
		Interim Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 fzmd-20170630.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure 0000319016 2017-01-01 2017-06-30 0000319016 2017-08-07 0000319016 2017-06-30 0000319016 2016-12-31 0000319016 2017-04-01 2017-06-30 0000319016 2016-04-01 2016-06-30 0000319016 2016-01-01 2016-06-30 0000319016 us-gaap:CommonStockMember 2016-12-31 0000319016 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000319016 us-gaap:RetainedEarningsMember 2016-12-31 0000319016 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0000319016 us-gaap:CommonStockMember 2017-06-30 0000319016 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000319016 us-gaap:RetainedEarningsMember 2017-06-30 0000319016 2015-12-31 0000319016 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsReceivableMember 2017-01-01 2017-06-30 0000319016 us-gaap:CostOfGoodsTotalMember 2017-01-01 2017-06-30 0000319016 fzmd:NC143FamilyHoldingsLimitedPartnershipMember 2016-12-19 2016-12-19 0000319016 fzmd:ReegMedicalIndustriesIncorporationMember 2016-12-19 2016-12-19 0000319016 us-gaap:InvestorMember 2016-12-19 2016-12-19 0000319016 us-gaap:ComputerEquipmentMember 2016-12-31 0000319016 us-gaap:FurnitureAndFixturesMember 2017-06-30 0000319016 us-gaap:FurnitureAndFixturesMember 2016-12-31 0000319016 us-gaap:LeaseholdImprovementsMember 2017-06-30 0000319016 us-gaap:LeaseholdImprovementsMember 2016-12-31 0000319016 us-gaap:OfficeEquipmentMember 2017-06-30 0000319016 us-gaap:OfficeEquipmentMember 2016-12-31 0000319016 us-gaap:FurnitureAndFixturesMember 2017-01-01 2017-06-30 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2016-10-31 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2016-07-01 2016-10-31 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2017-01-01 2017-06-30 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2017-06-30 0000319016 us-gaap:InvestorMember 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2017-06-30 0000319016 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2016-12-31 0000319016 us-gaap:AccountsPayableMember 2017-01-01 2017-06-30 0000319016 fzmd:FormerLawFirmMember us-gaap:AccountsPayableMember 2017-01-01 2017-06-30 0000319016 us-gaap:BeneficialOwnerMember us-gaap:AccountsPayableMember 2017-01-01 2017-06-30 0000319016 us-gaap:StockCompensationPlanMember fzmd:TwentySeventeenPlanMember 2017-01-01 2017-06-30 0000319016 2016-01-01 2016-12-31 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2017-04-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2016-04-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2017-01-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer1Member 2016-01-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2017-04-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2016-04-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2017-01-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer2Member 2016-01-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2017-04-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2016-04-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2017-01-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer3Member 2016-01-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2017-04-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2016-04-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2017-01-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember fzmd:Customer4Member 2016-01-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-04-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-04-01 2016-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-06-30 0000319016 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-06-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer1Member 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer1Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer2Member 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer2Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer3Member 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer3Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer4Member 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember fzmd:Customer4Member 2016-01-01 2016-12-31 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-06-30 0000319016 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2016-01-01 2016-12-31 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member 2017-04-01 2017-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member 2016-04-01 2016-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member 2017-01-01 2017-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember fzmd:Supplier1Member 2016-01-01 2016-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2017-04-01 2017-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2016-04-01 2016-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2017-01-01 2017-06-30 0000319016 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2016-01-01 2016-06-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2017-01-01 2017-06-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2017-04-01 2017-06-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2016-04-01 2016-06-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2016-01-01 2016-06-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2017-06-30 0000319016 fzmd:CPMMedicalConsultantsLLCMember 2016-12-31 0000319016 fzmd:TenPercentPromissoryNotesMember us-gaap:InvestorMember 2016-12-31 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2017-06-30 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2016-12-31 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2017-04-01 2017-06-30 0000319016 fzmd:AmBioStaffingLLCMember fzmd:PayrollProcessingEmployeeBenefitAdministrationAndRelatedHumanCapitalServicesMember 2017-01-01 2017-06-30 0000319016 us-gaap:SubsequentEventMember 2017-07-19 0000319016 us-gaap:SubsequentEventMember 2017-07-18 2017-07-19 Fuse Medical, Inc. 0000319016 10-Q 2017-06-30 false --12-31 No No Yes Smaller Reporting Company 15890808 Q2 2017 FZMD

445265

667475

216214

58065

18841

25326

29346

3528

709666

754394

5471

8931

3822

718959

767147

89174

83410

112140

77178

39877

5097

150000

664

160

391855

315845

230

687

392085

316532

158908

3192686

-3024720

-2900979

326874

450615

718959

767147

0.01

20000000

0.01

100000000

15890808

334672

120643

482829

313586

114992

20837

163302

102118

219680

99806

319527

211468

219286

182938

470028

411515

-307

-1580

996

3522

2853

7164

220282

186460

473188

420259

-602

-86654

-153661

-208791

6731

1750

13388

3500

43308

-7333

-88404

-123741

-212291

0.00

-0.01

-0.03

15890808

6890808

15890808

6890808

15890808

158908

3192686

-2900979

-123741

15890808

158908

3192686

-3024720

158149

-263173

-6485

-55730

25818

-9257

49072

-89858

34962

-14573

34781

91534

-46

-550

-222510

112338

300

-222210

112638

8157

120795

3500

<div> Note 1. Nature of Operations Overview The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Delaware corporation.  Effective May 28, 2014, the Company amended its certificate of incorporation to change its name from “GolfRounds.com, Inc.” to “Fuse Medical, Inc.” (the “Company”).  Then, also on May 28, 2014, the Company merged with and into Fuse Medical, LLC, with Fuse Medical, LLC surviving as a wholly owned subsidiary of Fuse Medical, Inc (“Legacy Fuse”).  The transaction was accounted for as a reverse merger with Fuse Medical, Inc. deemed the legal acquirer, and Fuse Medical, LLC deemed the accounting acquirer.  During 2015, Certificates of Termination were filed for Fuse Medical, LLC and its two subsidiaries. On December 19, 2016 (the “Closing Date”), the Company entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), and Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg (“RMI” and, together with NC 143, the “Investors”), pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date.  As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391.  The closing of the Purchase Agreement resulted in a change in control of the Company whereby the Investors acquired a majority interest in the Company. Effective as of the Closing Date, Mark W. Brooks became the Chairman of the Board of Directors and Christopher C. Reeg became the Chief Executive Officer of the Company. The Company distributes a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, and full spinal implants for trauma, degenerative disc disease and deformity indications (“Orthopedic Implants”). The Company also supports its broad portfolio of Orthopedic Implants with human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). The Company’s principal supplier is CPM Medical Consultants, LLC (“CPM”) a company owned and controlled by the Company’s Chairman of the Board of Directors. The Company strives to provide cost savings and quality products to its customers, which include hospitals and medical facilities. Basis of Presentation The interim condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading. The condensed balance sheet information as of December 31, 2016, was derived from the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017 (“2016 Annual Report”). These condensed financial statements should be read in conjunction with the 2016 Annual Report. The results of operations for the three and six-months ended June 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period. Going Concern The accompanying condensed financial statements have been prepared as if the Company will continue as a going concern. For the six-month period ended June 30, 2017, the Company had net cash used in operations of $222,510, of which $123,741 represented a net loss. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the ability of the Company’s management to successfully execute its restructuring and rebranding strategies and to achieve a level of profitability. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2016 audited financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. The Company’s management expects to fund its future business development activities and its working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time adequate funds are provided by operations. There can be no assurance that the Company’s financing efforts will be successful, or if the Company’s management will be able to achieve profitable operations. Additional financing, may include restrictions on the Company’s operations in the case of debt, or cause dilution for the Company’s stockholders in the case of equity financing. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</div>

<div> Note 6. Stockholders' Equity Stock Options Stock Incentive Plans The Company has a share-based compensation plan which provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors; the 2017 Equity Incentive Plan of Fuse Medical, Inc. (the “2017 Plan”), which was adopted by the Company’s Board of Directors on April 5, 2017. The awards are subject to a vesting schedule as set forth in individual agreements. No equity awards have been issued pursuant to the 2017 Plan.   The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the six-months ended June 30, 2017 is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No. of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at June 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Note 7. Concentrations Concentration of Revenues, Accounts Receivable and Suppliers For the three-months and six-months ended June 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   At June 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   The Company’s principal supplier is CPM and provided 10% or greater of the Company’s goods purchased for the periods presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> Note 8. Related Party Transactions The Company entered into a distributor agreement with CPM effective August 2, 2012, pursuant to which the Company acts as a non-exclusive distributor of certain amniotic membrane products. The term of the agreement is one year and renews on each annual anniversary date for successive one-year terms unless it is terminated in writing by either party. Effective January 1, 2017, this agreement was amended to expand and include Orthopedic Implants and a broader assortment of Biologics. (See Note 1) During the three-months ended June 30, 2017 and 2016 the Company sold $112,140 and $3,940, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the six-months ended June 30, 2017 and 2016 the Company sold $157,582 and $13,000, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the three-months ended June 30, 2017 and 2016 the Company purchased $112,665 and $13,200, respectively, of its products from CPM. During the six-months ended June 30, 2017 and 2016 the Company purchased $158,107 and $13,200, respectively, of its products from CPM. The balance due to CPM at June 30, 2017 and December 31, 2016 was $112,140 and $77,178, respectively, and are reflected within accounts payable – related parties on the accompanying condensed balance sheets. During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. The balance of the notes payable at June 30, 2017 and December 31, 2016 was $150,000. On December 19, 2016, the Company entered into the Purchase Agreement by and among the Company, NC 143, and RMI, pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. (See Note 1) During the three-months and six-months ended June 30, 2017, CPM provided shared services for back-office functions such as accounting, finance, supply chain management, and sales support. In addition, the Company’s Chief Executive Officer and Interim Chief Financial Officer provided services at no charge to the Company. The financial statements do not reflect an estimate of fair value of these services. Effective January 1, 2017 the Company engaged AmBio Staffing, LLC, a Texas licensed professional employment organization to provide payroll processing, employee benefit administration, and related human capital services. AmBio Staffing, LLC is owned and controlled by the Company’s Chairman of the Board of Directors. The balance due to AmBio Staffing, LLC at June 30, 2017 and December 31, 2016 was $8,660 and $0, respectively, and is reflected within accounts payable on the accompanying condensed balance sheets. For the three-months and six-months ended June 30, 2017, $2,757 and $6,877 of fees were paid to AmBio Staffing, LLC for such services, respectively and are reflected within general, administrative and other expenses on the accompanying condensed statements of operations. </div>

<div>   Note 9. Subsequent Events   On July 17, 2017, the Company entered into an assignment of sublease and consent, dated July 17, 2017 terminating all obligations of the Company under its assigned office sublease at 1300 Summit Avenue, Suite 670, Fort Worth, Texas 76102.   On July 19, 2017, the Company entered into a commercial property lease agreement for its new office space located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080, dated to be effective July 14, 2017, by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s Chairman of the Board of Directors. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.    <p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</div>

<div> Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates.  Significant estimates in the accompanying condensed financial statements include the allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards.</div>

<div> Reclassifications Certain amounts in the accompanying condensed financial statements as of June 30, 2016, and for the three-months and six-months then ended, have been reclassified to conform to the June 30, 2017 condensed financial statements for the three-months and six-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively.</div>

<div> Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at June 30, 2017 and 2016. The Company maintains its cash in financial institution deposit accounts that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through June 30, 2017. As of June 30, 2017, and December 31, 2016, there were deposits of $206,693 and $421,636, respectively, greater than federally insured limits.</div>

<div> Accounts Receivable and Allowance for Doubtful Accounts Receivable Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. </div>

<div> Inventories Inventories are stated at the lower of cost (first-in, first-out) or market.  Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit.</div>

<div> Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs).</div>

<div> Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures.  All other ASUs issued and not yet effective for the six-months ended June 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.</div>

<div> Property and equipment consisted of the following at June 30, 2017 and December 31, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,290</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,047</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,347</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,728</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,728</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,355</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,945</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,884</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,471</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,931</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the six-months ended June 30, 2017 is presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No. of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance outstanding at June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at June 30, 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304,788</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.22</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> For the three-months and six-months ended June 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> At June 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer 4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> The Company’s principal supplier is CPM and provided 10% or greater of the Company’s goods purchased for the periods presented below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Three-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Six-months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplier 1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Totals</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

5000000

400000

4000000

320000

64609

655391 1304788 609576

250000

206693

421636

29290

5047

6347

6728

1580

13355

43945

7884

35014

607

300

307

150000

0.10

0.18

principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share.

0.08

117500

18485

5096

January 27, 2014

M. Richard Cutler and Cutler Law Group, P.C.

Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc.

2014-04-21

43308

32052

11256

1304788

0.22

P4Y3M18D

P3Y9M18D

35000

183000

0.458

0.000

0.382

0.000

0.222

0.000

0.235

0.000

0.179

0.000

0.246

0.000

0.131

0.000

0.091

0.000

0.990

0.000

0.954

0.000

0.433

0.000

0.203

0.000

0.201

0.103

0.148

0.000

0.985

0.103

1.000

0.327

0.981

0.153

1.000

0.327

0.981

0.153

2012-08-02 P1Y

112140

3940

157582

13000

112665

13200

158107

13200

112140

77178

150000

8660

2757

6877

4000

2017-07-14 2017-12-31

EX-101.SCH 6 fzmd-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONDENSED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Nature of Operations link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Notes Payable - Related Parties link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Concentrations link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Concentrations (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Nature of Operations (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Significant Accounting Policies (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Property and Equipment (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Notes Payable - Related Parties (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Commitments and Contingencies (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Stockholders' Equity (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Related Party Transactions (Details Narrative) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Subsequent Events (Details Narrative) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 fzmd-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 fzmd-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 fzmd-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document And Entity Information Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Is Entity a Voluntary Filer Entity Voluntary Filers Is Entity's Reporting Status Current Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Trading Symbol Trading Symbol Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable, net of allowance of $0 Accounts Receivable Net Current Inventories Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Security deposit Deposits Assets Noncurrent Total assets Assets Liabilities and Stockholders' Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accounts payable - related parties Accounts Payable Related Parties Current Accrued expenses Accrued Liabilities Current Note payable - related parties Notes Payable Related Parties Classified Current Deferred rent - short term Deferred Rent Credit Current Total current liabilities Liabilities Current Deferred rent - long term Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders' equity: Stockholders Equity [Abstract] Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding Preferred Stock Value Common stock, $0.01 par value; 100,000,000 shares authorized, 15,890,808 shares issued and outstanding Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders' equity Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity Net of allowance, accounts receivable Allowance For Doubtful Accounts Receivable Current Preferred Stock Par Value Preferred Stock Par Or Stated Value Per Share Preferred Stock Shares Authorized Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Issued Preferred Stock Shares Outstanding Preferred Stock Shares Outstanding Common Stock Par Value Common Stock Par Or Stated Value Per Share Common Stock Shares Authorized Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Issued Common Stock Shares Outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenues Revenues Cost of revenues (primarily from related party, see note 8) Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] General, administrative and other Other General And Administrative Expense Loss on disposal of property and equipment Gain Loss On Sale Of Property Plant Equipment Depreciation Depreciation Total operating expenses Operating Expenses Operating loss Operating Income Loss Interest expense Interest Expense Related Party Extinguishment of debt Gains Losses On Extinguishment Of Debt Net loss Net Income Loss Net loss per common share - basic and diluted Earnings Per Share Basic And Diluted Weighted average number of common shares outstanding - basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning Balance, Amount Beginning Balance, Shares Shares Issued Net loss Ending Balance, Amount Ending Balance, Shares Consolidated Statements Of Cash Flows Statement Condensed Consolidated Statements Of Cash Flows Unaudited [Abstract] Cash flows from operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Extinguishment of debt Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other receivables Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accounts payable - related parties Increase Decrease In Accounts Payable Related Parties Accrued expenses Increase Decrease In Accrued Liabilities Deferred revenues Increase Decrease In Deferred Revenue Deferred rent Increase Decrease In Deferred Charges Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Proceeds from the disposal of property and equipment Proceeds From Sale Of Property Plant And Equipment Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Net (decrease) increase in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents - beginning of period Cash and cash equivalents - end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Interest Paid Interest Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Nature of Operations Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Notes payable related party. Debt Disclosure [Abstract] Notes Payable – Related Parties Notes Payable Related Party [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Stockholders Equity Stockholders Equity Deficit [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Nature of operations and going concern. Nature Of Operations And Going Concern [Abstract] Concentrations Concentration Risk Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Notes to Financial Statements Notes To Financial Statements [Abstract] Subsequent Events Subsequent Events [Text Block] Use of Estimates Use Of Estimates Earnings (Loss) Per Share Earnings Per Share Policy [Text Block] Fair Value Measurements Fair Value Of Financial Instruments Policy Reclassifications Prior Period Reclassification Adjustment Description Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Accounts Receivable and Allowance for Doubtful Accounts Receivable Trade And Other Accounts Receivable Policy Inventories Inventory Policy [Text Block] Income Taxes Income Tax Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Property and Equipment Property Plant And Equipment [Text Block] Stockholders Equity Tables Stockholders Equity Deficit Tables [Abstract] Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Concentrations details. Concentrations Details [Abstract] Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenues [Member] Sales Revenue Net [Member] Accounts Receivable [Member] Accounts Receivable [Member] Goods Purchased [Member] Cost Of Goods Total [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration of Revenues, Accounts Receivable and Suppliers Schedules Of Concentration Of Risk By Risk Factor [Text Block] Proceeds from issuance of common stock, net of offering costs. Nature of operations and going concern. Nature of operations and going concern. Nature Of Operations And Going Concern [Table] Nature Of Operations And Going Concern [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] NC 143 Family Holdings, Limited Partnership. NC 143 Family Holdings, LP [Member] N C143 Family Holdings Limited Partnership [Member] Reeg Medical Industries, Incorporation. RMI [Member] Reeg Medical Industries Incorporation [Member] Mark W. Brooks and Christopher C. Reeg [Member] Investor [Member] Nature Of Operations And Going Concern [Line Items] Nature Of Operations And Going Concern [Line Items] Sale of common shares Stock Issued During Period Shares New Issues Gross proceeds from sale of common shares Proceeds From Issuance Of Common Stock Direct offering costs Payments Of Stock Issuance Costs Net proceeds from sale of common stock Proceeds From Issuance Of Common Stock Net Of Offering Costs Net cash (used in) provided by operating activities Options to purchase included in common stock equivalents Options to purchase included in common stock equivalents Options To Purchase Included In Common Stock Equivalents Cash equivalents Cash Equivalents At Carrying Value FDIC insurance limit Cash F D I C Insured Amount Deposits greater than federally insured limit Cash Uninsured Amount Liabilities for uncertain tax positions, current Liability For Uncertain Tax Positions Current Liabilities for uncertain tax positions, noncurrent Liability For Uncertain Tax Positions Noncurrent Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Computer equipment [Member] Computer Equipment [Member] Furniture and fixtures [Member] Furniture And Fixtures [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Office equipment [Member] Office Equipment [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less: accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Depreciation expense Sale of property and equipment Property Plant And Equipment Disposals Gain (loss) on disposals of property and equipment Debt Instrument [Table] Debt Instrument [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Ten percent promissory notes. 10% Promissory Notes [Member] Ten Percent Promissory Notes [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Accrued expenses [Member] Accounts Payable And Accrued Liabilities [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Convertible notes payable - related parties Convertible Notes Payable Current Interest rate of promissory notes Debt Conversion Original Debt Interest Rate Of Debt Debt Instrument, description Debt Instrument Call Feature Conversion price of common stock Debt Instrument Convertible Conversion Price1 Recognition of beneficial conversion feature on convertible promissory notes issued to related parties Debt Instrument Convertible Beneficial Conversion Feature Interest expense on notes payable - related parties Accrued interest payable Interest Payable Current Commitments and contingencies. Commitments and contingencies. Commitments And Contingencies [Table] Commitments And Contingencies [Table] Extinguishment of Debt Extinguishment Of Debt [Axis] Extinguishment of Debt, Type Extinguishment Of Debt Type [Domain] Accounts Payable [Member] Accounts Payable [Member] Former law firm. Former Law Firm [Member] Former Law Firm [Member] Beneficial Owners [Member] Beneficial Owner [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Loss contingency, complaint filing date Loss Contingency Lawsuit Filing Date Loss contingency, name of plaintiff Loss Contingency Name Of Plaintiff Loss contingency, name of defendants Loss Contingency Name Of Defendant Loss contingency, date of complaint dismissal Loss Contingency Date Of Dismissal Gain on extinguishment of debt Amount of debt extinguished Extinguishment Of Debt Amount EX-101.PRE 10 fzmd-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 07, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Fuse Medical, Inc.
Entity Central Index Key	0000319016
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		15,890,808
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017
Trading Symbol	FZMD

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 445,265	$ 667,475
Accounts receivable, net of allowance of $0	216,214	58,065
Inventories	18,841	25,326
Prepaid expenses and other current assets	29,346	3,528
Total current assets	709,666	754,394
Property and equipment, net	5,471	8,931
Security deposit	3,822	3,822
Total assets	718,959	767,147
Current liabilities:
Accounts payable	89,174	83,410
Accounts payable - related parties	112,140	77,178
Accrued expenses	39,877	5,097
Note payable - related parties	150,000	150,000
Deferred rent - short term	664	160
Total current liabilities	391,855	315,845
Deferred rent - long term	230	687
Total liabilities	392,085	316,532
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 20,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized, 15,890,808 shares issued and outstanding	158,908	158,908
Additional paid-in capital	3,192,686	3,192,686
Accumulated deficit	(3,024,720)	(2,900,979)
Total stockholders' equity	326,874	450,615
Total liabilities and stockholders' equity	$ 718,959	$ 767,147

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Net of allowance, accounts receivable	$ 0	$ 0
Preferred Stock Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	20,000,000	20,000,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	100,000,000	100,000,000
Common Stock Shares Issued	15,890,808	15,890,808
Common Stock Shares Outstanding	15,890,808	15,890,808

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues	$ 334,672	$ 120,643	$ 482,829	$ 313,586
Cost of revenues (primarily from related party, see note 8)	114,992	20,837	163,302	102,118
Gross profit	219,680	99,806	319,527	211,468
Operating expenses:
General, administrative and other	219,286	182,938	470,028	411,515
Loss on disposal of property and equipment			307	1,580
Depreciation	996	3,522	2,853	7,164
Total operating expenses	220,282	186,460	473,188	420,259
Operating loss	(602)	(86,654)	(153,661)	(208,791)
Interest expense	(6,731)	(1,750)	(13,388)	(3,500)
Extinguishment of debt			43,308
Net loss	$ (7,333)	$ (88,404)	$ (123,741)	$ (212,291)
Net loss per common share - basic and diluted	$ 0.00	$ (0.01)	$ (0.01)	$ (0.03)
Weighted average number of common shares outstanding - basic and diluted	15,890,808	6,890,808	15,890,808	6,890,808

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance, Amount at Dec. 31, 2016	$ 450,615	$ 158,908	$ 3,192,686	$ (2,900,979)
Beginning Balance, Shares at Dec. 31, 2016		15,890,808
Net loss	(123,741)			(123,741)
Ending Balance, Amount at Jun. 30, 2017	$ 326,874	$ 158,908	$ 3,192,686	$ (3,024,720)
Ending Balance, Shares at Jun. 30, 2017		15,890,808

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (123,741)	$ (212,291)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	2,853	7,164
Loss on disposal of property and equipment	307	1,580
Extinguishment of debt	(43,308)
Changes in operating assets and liabilities
Accounts receivable	(158,149)	263,173
Inventories	6,485	55,730
Prepaid expenses and other receivables	(25,818)	9,257
Accounts payable	49,072	(89,858)
Accounts payable - related parties	34,962	(14,573)
Accrued expenses	34,781	72
Deferred revenues		91,534
Deferred rent	46	550
Net cash (used in) provided by operating activities	(222,510)	112,338
Cash flows from investing activities
Proceeds from the disposal of property and equipment	300	300
Net cash provided by investing activities	300	300
Net (decrease) increase in cash and cash equivalents	(222,210)	112,638
Cash and cash equivalents - beginning of period	667,475	8,157
Cash and cash equivalents - end of period	$ 445,265	120,795
Supplemental disclosure of cash flow information:
Interest Paid		$ 3,500

XML 17 R7.htm IDEA: XBRL DOCUMENT

Nature of Operations	6 Months Ended
Nature of Operations	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations	Note 1. Nature of Operations Overview The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Delaware corporation. Effective May 28, 2014, the Company amended its certificate of incorporation to change its name from “GolfRounds.com, Inc.” to “Fuse Medical, Inc.” (the “Company”). Then, also on May 28, 2014, the Company merged with and into Fuse Medical, LLC, with Fuse Medical, LLC surviving as a wholly owned subsidiary of Fuse Medical, Inc (“Legacy Fuse”). The transaction was accounted for as a reverse merger with Fuse Medical, Inc. deemed the legal acquirer, and Fuse Medical, LLC deemed the accounting acquirer. During 2015, Certificates of Termination were filed for Fuse Medical, LLC and its two subsidiaries. On December 19, 2016 (the “Closing Date”), the Company entered into a definitive Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), and Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg (“RMI” and, together with NC 143, the “Investors”), pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. The closing of the Purchase Agreement resulted in a change in control of the Company whereby the Investors acquired a majority interest in the Company. Effective as of the Closing Date, Mark W. Brooks became the Chairman of the Board of Directors and Christopher C. Reeg became the Chief Executive Officer of the Company. The Company distributes a broad portfolio of orthopedic implants including internal and external fixation products, upper and lower extremity plating and total joint reconstruction, soft tissue fixation and augmentation for sports medicine procedures, and full spinal implants for trauma, degenerative disc disease and deformity indications (“Orthopedic Implants”). The Company also supports its broad portfolio of Orthopedic Implants with human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). The Company’s principal supplier is CPM Medical Consultants, LLC (“CPM”) a company owned and controlled by the Company’s Chairman of the Board of Directors. The Company strives to provide cost savings and quality products to its customers, which include hospitals and medical facilities. Basis of Presentation The interim condensed financial statements included herein reflect all material adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) which, in the opinion of the Company’s management, are ordinary and necessary for a fair presentation of results for the interim periods. Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The Company’s management believes the disclosures are adequate to make the information presented not misleading. The condensed balance sheet information as of December 31, 2016, was derived from the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on March 20, 2017 (“2016 Annual Report”). These condensed financial statements should be read in conjunction with the 2016 Annual Report. The results of operations for the three and six-months ended June 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or for any other period. Going Concern The accompanying condensed financial statements have been prepared as if the Company will continue as a going concern. For the six-month period ended June 30, 2017, the Company had net cash used in operations of $222,510, of which $123,741 represented a net loss. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the ability of the Company’s management to successfully execute its restructuring and rebranding strategies and to achieve a level of profitability. As a result, the Company’s independent registered public accounting firm, in its report on the Company’s 2016 audited financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. The Company’s management expects to fund its future business development activities and its working capital needs largely from improved future operations and other traditional financing sources, such as a revolving line of credit facility, term notes, or additional private placements until such time adequate funds are provided by operations. There can be no assurance that the Company’s financing efforts will be successful, or if the Company’s management will be able to achieve profitable operations. Additional financing, may include restrictions on the Company’s operations in the case of debt, or cause dilution for the Company’s stockholders in the case of equity financing. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies	6 Months Ended
Significant Accounting Policies	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies	Note 2. Significant Accounting Policies Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying condensed financial statements include the allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards. Earnings (Loss) Per Share The Company’s computation of Earnings (loss) Per Share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that would have occurred if securities or other contracts to issue common shares (e.g., warrants and options) had been exercised or converted into common shares at the beginning of the period, or issuance date, if later, and had shared in the net income (loss) of the Company. Diluted EPS is computed using the treasury stock method, which assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common shares at the average market price during the period. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of June 30, 2017, and 2016, common stock equivalents included options to purchase 1,304,788 and 609,576 common shares, respectively. These instruments are not considered in the calculation of diluted loss per share because the effect would be anti-dilutive. Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets, Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities, and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates. Reclassifications Certain amounts in the accompanying condensed financial statements as of June 30, 2016, and for the three-months and six-months then ended, have been reclassified to conform to the June 30, 2017 condensed financial statements for the three-months and six-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at June 30, 2017 and 2016. The Company maintains its cash in financial institution deposit accounts that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through June 30, 2017. As of June 30, 2017, and December 31, 2016, there were deposits of $206,693 and $421,636, respectively, greater than federally insured limits. Accounts Receivable and Allowance for Doubtful Accounts Receivable Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. Inventories Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. Income Taxes The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of June 30, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs). Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro-rata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures. All other ASUs issued and not yet effective for the six-months ended June 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Jun. 30, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

Note 3. Property and Equipment

Property and equipment consisted of the following at June 30, 2017 and December 31, 2016:

	June 30, 2017			December 31, 2016
Computer equipment	$	-		$	29,290
Furniture and fixtures		5,047			6,347
Leasehold improvements		6,728			6,728
Office equipment		1,580			1,580
		13,355			43,945
Less: accumulated depreciation		(7,884	)		(35,014	)
Property and equipment, net	$	5,471		$	8,931

XML 20 R10.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Parties	6 Months Ended
Notes Payable - Related Parties	Jun. 30, 2017
Debt Disclosure [Abstract]
Notes Payable – Related Parties	Note 4. Notes Payable – Related Parties During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. This resulted in a beneficial conversion feature in the aggregate amount of $117,500, which was treated as a discount to each of the promissory notes and amortized over the term of each respective promissory note, maturing on December 31, 2016, the date in which the beneficial conversion feature was fully amortized. During the three-months ended June 30, 2017 and 2016, interest expense of $6,731 and $1,750, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. During the six-months ended June 30, 2017 and 2016, interest expense of $13,388 and $3,500, respectively, was recognized on outstanding notes payable – related parties and are reflected within interest expense on the accompanying condensed statements of operations. As of June 30, 2017, and December 31, 2016, accrued interest payable was $18,485 and $5,096, respectively, which is included in accrued expenses on the accompanying condensed balance sheets.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 5. Commitments and Contingencies Legal Matters On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 2014-03355, against Legacy Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc. (the “Defendants”). On April 21, 2014, the complaint was dismissed for “want of prosecution.” On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff, as more fully described in “Legal Matters” included in Note 6 in our 2016 Annual Report, which is herein incorporated by reference. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set. The Company’s management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect our interests. Accounts Payable During the six-months ended June 30, 2017, the Company recorded a gain of $43,308 on extinguishment of long-aged outstanding payables owed to a former law firm for $32,052 and liabilities aggregating $11,256 owed to the Company’s beneficial owners for services provided to the Company and is reflected within extinguishment of debt on the accompanying condensed statements of operations. The Company’s management believes if these items were contested, the probable outcome would be favorable primarily due to statute of limitations.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

6 Months Ended

Jun. 30, 2017

Stockholders Equity Deficit [Abstract]

Stockholders' Equity

Note 6. Stockholders' Equity

Stock Options

Stock Incentive Plans

The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the six-months ended June 30, 2017 is presented below:

	No. of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance outstanding at December 31, 2016		1,304,788	$	0.22		4.3	$	35,000
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Balance outstanding at June 30, 2017		1,304,788	$	0.22		3.8	$	183,000
Exercisable at June 30, 2017		1,304,788	$	0.22		3.8	$	183,000

XML 23 R13.htm IDEA: XBRL DOCUMENT

Concentrations

6 Months Ended

Jun. 30, 2017

Nature Of Operations And Going Concern [Abstract]

Concentrations

Note 7. Concentrations

Concentration of Revenues, Accounts Receivable and Suppliers

For the three-months and six-months ended June 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:

	For the Three-months Ended June 30, 2017			For the Three-months Ended June 30, 2016			For the Six-months Ended June 30, 2017			For the Six-months Ended June 30, 2016
Customer 1		45.8	%		0.0	%		38.2	%		0.0	%
Customer 2		22.2	%		0.0	%		23.5	%		0.0	%
Customer 3		17.9	%		0.0	%		24.6	%		0.0	%
Customer 4		13.1	%		0.0	%		9.1	%		0.0	%
Totals		99.0	%		0.0	%		95.4	%		0.0	%

At June 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:

	June 30, 2017			December 31, 2016
Customer 1		43.3	%		0.0	%
Customer 2		20.3	%		0.0	%
Customer 3		20.1	%		10.3	%
Customer 4		14.8	%		0.0	%
Totals		98.5	%		10.3	%

The Company’s principal supplier is CPM and provided 10% or greater of the Company’s goods purchased for the periods presented below:

For the Three-months Ended

June 30, 2017

For the Three-months Ended

June 30, 2016

For the Six-months Ended

June 30, 2017

For the Six-months Ended

June 30, 2016

Supplier 1

100.0

32.7

98.1

15.3

Totals

100.0

32.7

98.1

15.3

XML 24 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 8. Related Party Transactions The Company entered into a distributor agreement with CPM effective August 2, 2012, pursuant to which the Company acts as a non-exclusive distributor of certain amniotic membrane products. The term of the agreement is one year and renews on each annual anniversary date for successive one-year terms unless it is terminated in writing by either party. Effective January 1, 2017, this agreement was amended to expand and include Orthopedic Implants and a broader assortment of Biologics. (See Note 1) During the three-months ended June 30, 2017 and 2016 the Company sold $112,140 and $3,940, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the six-months ended June 30, 2017 and 2016 the Company sold $157,582 and $13,000, respectively, of its products purchased from CPM that are reflected in cost of revenues on the accompanying condensed statements of operations. During the three-months ended June 30, 2017 and 2016 the Company purchased $112,665 and $13,200, respectively, of its products from CPM. During the six-months ended June 30, 2017 and 2016 the Company purchased $158,107 and $13,200, respectively, of its products from CPM. The balance due to CPM at June 30, 2017 and December 31, 2016 was $112,140 and $77,178, respectively, and are reflected within accounts payable – related parties on the accompanying condensed balance sheets. During July 2016 through October 2016, the Company obtained three short-term loans from the Investors in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, and 18% interest per annum after December 31, 2016, which principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. The balance of the notes payable at June 30, 2017 and December 31, 2016 was $150,000. On December 19, 2016, the Company entered into the Purchase Agreement by and among the Company, NC 143, and RMI, pursuant to which NC 143 acquired 5,000,000 shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4,000,000 shares of the Company’s common stock for a purchase price of $320,000, effective as of the Closing Date. As direct offering costs amounted to $64,609, net proceeds from the sale of these shares were $655,391. (See Note 1) During the three-months and six-months ended June 30, 2017, CPM provided shared services for back-office functions such as accounting, finance, supply chain management, and sales support. In addition, the Company’s Chief Executive Officer and Interim Chief Financial Officer provided services at no charge to the Company. The financial statements do not reflect an estimate of fair value of these services. Effective January 1, 2017 the Company engaged AmBio Staffing, LLC, a Texas licensed professional employment organization to provide payroll processing, employee benefit administration, and related human capital services. AmBio Staffing, LLC is owned and controlled by the Company’s Chairman of the Board of Directors. The balance due to AmBio Staffing, LLC at June 30, 2017 and December 31, 2016 was $8,660 and $0, respectively, and is reflected within accounts payable on the accompanying condensed balance sheets. For the three-months and six-months ended June 30, 2017, $2,757 and $6,877 of fees were paid to AmBio Staffing, LLC for such services, respectively and are reflected within general, administrative and other expenses on the accompanying condensed statements of operations.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2017
Notes To Financial Statements [Abstract]
Subsequent Events	Note 9. Subsequent Events On July 17, 2017, the Company entered into an assignment of sublease and consent, dated July 17, 2017 terminating all obligations of the Company under its assigned office sublease at 1300 Summit Avenue, Suite 670, Fort Worth, Texas 76102. On July 19, 2017, the Company entered into a commercial property lease agreement for its new office space located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080, dated to be effective July 14, 2017, by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s Chairman of the Board of Directors. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017. F-1

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2017
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the condensed financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying condensed financial statements include the allowance for doubtful accounts, valuation of inventories, the estimates of fixed assets useful lives, the valuation of property and equipment, the valuation allowance on deferred tax assets, and the fair value calculation of stock-based awards.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company’s computation of Earnings (loss) Per Share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that would have occurred if securities or other contracts to issue common shares (e.g., warrants and options) had been exercised or converted into common shares at the beginning of the period, or issuance date, if later, and had shared in the net income (loss) of the Company. Diluted EPS is computed using the treasury stock method, which assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common shares at the average market price during the period. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of June 30, 2017, and 2016, common stock equivalents included options to purchase 1,304,788 and 609,576 common shares, respectively. These instruments are not considered in the calculation of diluted loss per share because the effect would be anti-dilutive.
Fair Value Measurements	Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets, Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities, and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates.
Reclassifications	Reclassifications Certain amounts in the accompanying condensed financial statements as of June 30, 2016, and for the three-months and six-months then ended, have been reclassified to conform to the June 30, 2017 condensed financial statements for the three-months and six-months then ended. These include deferred rent and depreciation expense, previously reported as a component of accrued expenses and general, administrative and other expenses, respectively.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three-months or less at the time of purchase to be cash equivalents. There were no cash equivalents at June 30, 2017 and 2016. The Company maintains its cash in financial institution deposit accounts that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through June 30, 2017. As of June 30, 2017, and December 31, 2016, there were deposits of $206,693 and $421,636, respectively, greater than federally insured limits.
Accounts Receivable and Allowance for Doubtful Accounts Receivable	Accounts Receivable and Allowance for Doubtful Accounts Receivable Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. Payment trends and receivable amounts outstanding for an extended period beyond contractual terms are examples of these indicators. Accounts deemed uncollectible are written off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts.
Inventories	Inventories Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit.
Income Taxes	Income Taxes The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of June 30, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists, (ii) the fees are fixed or determinable, (iii) no significant Company obligations remain, and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs).
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the pro-rata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management do not believe that this guidance will have a material impact on its financial statements and disclosures. All other ASUs issued and not yet effective for the six-months ended June 30, 2017, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s financial position of results of operations.

XML 27 R17.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2017

Property Plant And Equipment [Abstract]

Property and Equipment

Property and equipment consisted of the following at June 30, 2017 and December 31, 2016:

	June 30, 2017			December 31, 2016
Computer equipment	$	-		$	29,290
Furniture and fixtures		5,047			6,347
Leasehold improvements		6,728			6,728
Office equipment		1,580			1,580
		13,355			43,945
Less: accumulated depreciation		(7,884	)		(35,014	)
Property and equipment, net	$	5,471		$	8,931

XML 28 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2017

Stockholders Equity Deficit Tables [Abstract]

Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity

The following summary reflects equity awards granted prior to the 2017 Plan and the stock option activity during the six-months ended June 30, 2017 is presented below:

	No. of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
Balance outstanding at December 31, 2016		1,304,788	$	0.22		4.3	$	35,000
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
Balance outstanding at June 30, 2017		1,304,788	$	0.22		3.8	$	183,000
Exercisable at June 30, 2017		1,304,788	$	0.22		3.8	$	183,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

Concentrations (Tables)

6 Months Ended

Jun. 30, 2017

Revenues [Member]

Concentration Risk [Line Items]

Concentration of Revenues, Accounts Receivable and Suppliers

For the three-months and six-months ended June 30, 2017 and 2016, the Company had significant customers with individual percentage of total revenues equaling 10% or greater as follows:

	For the Three-months Ended June 30, 2017			For the Three-months Ended June 30, 2016			For the Six-months Ended June 30, 2017			For the Six-months Ended June 30, 2016
Customer 1		45.8	%		0.0	%		38.2	%		0.0	%
Customer 2		22.2	%		0.0	%		23.5	%		0.0	%
Customer 3		17.9	%		0.0	%		24.6	%		0.0	%
Customer 4		13.1	%		0.0	%		9.1	%		0.0	%
Totals		99.0	%		0.0	%		95.4	%		0.0	%

Accounts Receivable [Member]

Concentration Risk [Line Items]

Concentration of Revenues, Accounts Receivable and Suppliers

At June 30, 2017 and December 31, 2016, concentration of accounts receivable with significant customers representing 10% or greater of accounts receivable was as follows:

	June 30, 2017			December 31, 2016
Customer 1		43.3	%		0.0	%
Customer 2		20.3	%		0.0	%
Customer 3		20.1	%		10.3	%
Customer 4		14.8	%		0.0	%
Totals		98.5	%		10.3	%

Goods Purchased [Member]

Concentration Risk [Line Items]

Concentration of Revenues, Accounts Receivable and Suppliers

The Company’s principal supplier is CPM and provided 10% or greater of the Company’s goods purchased for the periods presented below:

For the Three-months Ended

June 30, 2017

For the Three-months Ended

June 30, 2016

For the Six-months Ended

June 30, 2017

For the Six-months Ended

June 30, 2016

Supplier 1

100.0

32.7

98.1

15.3

Totals

100.0

32.7

98.1

15.3

XML 30 R20.htm IDEA: XBRL DOCUMENT

Nature of Operations (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
Nature of Operations (Details Narrative) - USD ($)	Dec. 19, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Nature Of Operations And Going Concern [Line Items]
Net loss		$ (7,333)	$ (88,404)	$ (123,741)	$ (212,291)
Net cash (used in) provided by operating activities				$ (222,510)	$ 112,338
NC 143 Family Holdings, LP [Member]
Nature Of Operations And Going Concern [Line Items]
Sale of common shares	5,000,000
Gross proceeds from sale of common shares	$ 400,000
RMI [Member]
Nature Of Operations And Going Concern [Line Items]
Sale of common shares	4,000,000
Gross proceeds from sale of common shares	$ 320,000
Mark W. Brooks and Christopher C. Reeg [Member]
Nature Of Operations And Going Concern [Line Items]
Direct offering costs	64,609
Net proceeds from sale of common stock	$ 655,391

XML 31 R21.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Accounting Policies [Abstract]
Options to purchase included in common stock equivalents	1,304,788	609,576
Cash equivalents	$ 0	$ 0
FDIC insurance limit	250,000
Deposits greater than federally insured limit	206,693		$ 421,636
Liabilities for uncertain tax positions, current	0
Liabilities for uncertain tax positions, noncurrent	$ 0

XML 32 R22.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 13,355	$ 43,945
Less: accumulated depreciation	(7,884)	(35,014)
Property and equipment, net	5,471	8,931
Computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		29,290
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,047	6,347
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,728	6,728
Office equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,580	$ 1,580

XML 33 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property Plant And Equipment [Line Items]
Depreciation expense	$ 996	$ 3,522	$ 2,853	$ 7,164
Proceeds from the disposal of property and equipment			300	300
Gain (loss) on disposals of property and equipment			(307)	$ (1,580)
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Sale of property and equipment			607
Proceeds from the disposal of property and equipment			300
Gain (loss) on disposals of property and equipment			$ 307

XML 34 R24.htm IDEA: XBRL DOCUMENT

Notes Payable - Related Parties (Details Narrative) - USD ($)	3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Oct. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Debt Instrument [Line Items]
Interest expense on notes payable - related parties	$ 6,731	$ 1,750		$ 13,388	$ 3,500
Accrued expenses [Member]
Debt Instrument [Line Items]
Accrued interest payable	$ 18,485			18,485		$ 5,096
Mark W. Brooks and Christopher C. Reeg [Member]
Debt Instrument [Line Items]
Recognition of beneficial conversion feature on convertible promissory notes issued to related parties				$ 117,500
10% Promissory Notes [Member] \| Mark W. Brooks and Christopher C. Reeg [Member]
Debt Instrument [Line Items]
Convertible notes payable - related parties			$ 150,000
Interest rate of promissory notes			10.00%	18.00%
Debt Instrument, description				principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share.
Conversion price of common stock	$ 0.08			$ 0.08

XML 35 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	6 Months Ended
Commitments and Contingencies (Details Narrative)	Jun. 30, 2017 USD ($)
Commitments And Contingencies [Line Items]
Loss contingency, complaint filing date	January 27, 2014
Loss contingency, name of plaintiff	M. Richard Cutler and Cutler Law Group, P.C.
Loss contingency, name of defendants	Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and GolfRounds.com, Inc.
Loss contingency, date of complaint dismissal	Apr. 21, 2014
Gain on extinguishment of debt	$ 43,308
Accounts Payable [Member]
Commitments And Contingencies [Line Items]
Gain on extinguishment of debt	43,308
Accounts Payable [Member] \| Former Law Firm [Member]
Commitments And Contingencies [Line Items]
Amount of debt extinguished	32,052
Accounts Payable [Member] \| Beneficial Owners [Member]
Commitments And Contingencies [Line Items]
Amount of debt extinguished	$ 11,256

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Narrative)	6 Months Ended
Stockholders' Equity (Details Narrative)	Jun. 30, 2017 shares
2017 Plan [Member] \| Share-Based Compensation Plan [Member]
Class Of Stock [Line Items]
Equity awards issued	0

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
No. of shares, Abstract
No. of Shares, Beginning Balance	1,304,788
No. of Shares, Ending Balance	1,304,788	1,304,788
Exercisable, No. Of Shares	1,304,788
Weighted average exercise price, Abstract
Weighted Average Exercise Price, Beginning Balance	$ 0.22
Weighted Average Exercise Price, Ending Balance	0.22	$ 0.22
Exercisable, Weighted Average Exercise Price	$ 0.22
Weighted average remaining contractual term, Abstract
Weighted Average Remaining Contractual Term, Balance outstanding	3 years 9 months 18 days	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, Exercisable	3 years 9 months 18 days
Aggregate intrinsic value, Abstract
Aggregate Intrinsic Value, Balance outstanding	$ 183,000	$ 35,000
Aggregate Intrinsic Value, Exercisable	$ 183,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) - Customer Concentration Risk [Member] - Revenues [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	99.00%	0.00%	95.40%	0.00%
Customer 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	45.80%	0.00%	38.20%	0.00%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	22.20%	0.00%	23.50%	0.00%
Customer 3 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.90%	0.00%	24.60%	0.00%
Customer 4 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.10%	0.00%	9.10%	0.00%

XML 39 R29.htm IDEA: XBRL DOCUMENT

Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) - Credit Concentration Risk [Member] - Accounts Receivable [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	98.50%	10.30%
Customer 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	43.30%	0.00%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	20.30%	0.00%
Customer 3 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	20.10%	10.30%
Customer 4 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	14.80%	0.00%

XML 40 R30.htm IDEA: XBRL DOCUMENT

Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) - Supplier Concentration Risk [Member] - Goods Purchased [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	100.00%	32.70%	98.10%	15.30%
Supplier 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100.00%	32.70%	98.10%	15.30%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)		3 Months Ended		4 Months Ended	6 Months Ended
	Dec. 19, 2016	Jun. 30, 2017	Jun. 30, 2016	Oct. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Accounts payable - related parties		$ 112,140			$ 112,140		$ 77,178
Notes payable to related party		150,000			$ 150,000		150,000
CPM [Member]
Related Party Transaction [Line Items]
Distributor agreement effective date					Aug. 02, 2012
Distributor agreement term					1 year
Amount of transaction related to sale of products reflected in cost of sales		112,140	$ 3,940		$ 157,582	$ 13,000
Purchases from supplier		112,665	$ 13,200		158,107	$ 13,200
Accounts payable - related parties		$ 112,140			$ 112,140		77,178
Mark W. Brooks and Christopher C. Reeg [Member]
Related Party Transaction [Line Items]
Direct offering costs	$ 64,609
Net proceeds from sale of common stock	$ 655,391
Mark W. Brooks and Christopher C. Reeg [Member] \| 10% Promissory Notes [Member]
Related Party Transaction [Line Items]
Convertible notes payable - related parties				$ 150,000
Interest rate of promissory notes				10.00%	18.00%
Debt Instrument, description					principal shall be due and payable, upon demand of the payee, at any time after the earlier of: (i) December 31, 2016, or (ii) upon a change in control of the Company. Notwithstanding, on or after January 16, 2017, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share.
Conversion price of common stock		$ 0.08			$ 0.08
Notes payable to related party		$ 150,000			$ 150,000		150,000
NC 143 [Member]
Related Party Transaction [Line Items]
Sale of common shares	5,000,000
Gross proceeds from sale of common shares	$ 400,000
RMI [Member]
Related Party Transaction [Line Items]
Sale of common shares	4,000,000
Gross proceeds from sale of common shares	$ 320,000
AmBio Staffing, LLC [Member] \| Payroll Processing, Employee Benefit Administration, and Related Human Capital Services [Member]
Related Party Transaction [Line Items]
Due to related parties		8,660			8,660		$ 0
Fees paid for services		$ 2,757			$ 6,877

XML 42 R32.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Jul. 19, 2017 USD ($)
Subsequent Event [Line Items]
Rent paid	$ 4,000
Lease term begins	Jul. 14, 2017
Lease term ends	Dec. 31, 2017

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 93 139 1 false 32 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.fusemedical.com/20170630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.fusemedical.com/20170630/taxonomy/role/StatementCONDENSEDBALANCESHEETS CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://www.fusemedical.com/20170630/taxonomy/role/StatementCONDENSEDBALANCESHEETSParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.fusemedical.com/20170630/taxonomy/role/StatementCONDENSEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.fusemedical.com/20170630/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.fusemedical.com/20170630/taxonomy/role/StatementCONDENSEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Nature of Operations Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureNatureOfOperations Nature of Operations Notes 7 false false R8.htm 100070 - Disclosure - Significant Accounting Policies Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 100080 - Disclosure - Property and Equipment Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 100090 - Disclosure - Notes Payable - Related Parties Notes http://www.fusemedical.com/20170630/taxonomy/role/DisclosureNotesPayableRelatedParties Notes Payable - Related Parties Notes 10 false false R11.htm 100100 - Disclosure - Commitments and Contingencies Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 100110 - Disclosure - Stockholders' Equity Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 12 false false R13.htm 100120 - Disclosure - Concentrations Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureConcentrations Concentrations Notes 13 false false R14.htm 100130 - Disclosure - Related Party Transactions Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 100140 - Disclosure - Subsequent Events Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 100150 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSignificantAccountingPolicies 16 false false R17.htm 100160 - Disclosure - Property and Equipment (Tables) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipment 17 false false R18.htm 100170 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.fusemedical.com/20170630/taxonomy/role/DisclosureStockholdersEquity 18 false false R19.htm 100180 - Disclosure - Concentrations (Tables) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureConcentrationsTables Concentrations (Tables) Tables http://www.fusemedical.com/20170630/taxonomy/role/DisclosureConcentrations 19 false false R20.htm 100190 - Disclosure - Nature of Operations (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureNatureOfOperationsDetailsNarrative Nature of Operations (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureNatureOfOperations 20 false false R21.htm 100200 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies 21 false false R22.htm 100210 - Disclosure - Property and Equipment (Details) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipmentTables 22 false false R23.htm 100220 - Disclosure - Property and Equipment (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosurePropertyAndEquipmentTables 23 false false R24.htm 100230 - Disclosure - Notes Payable - Related Parties (Details Narrative) Notes http://www.fusemedical.com/20170630/taxonomy/role/DisclosureNotesPayableRelatedPartiesDetailsNarrative Notes Payable - Related Parties (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureNotesPayableRelatedParties 24 false false R25.htm 100240 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 100250 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureStockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureStockholdersEquityTables 26 false false R27.htm 100260 - Disclosure - Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureStockholdersEquitySummaryOfEquityAwardsGrantedPriorTo2017PlanAndStockOptionActivityDetails Stockholders' Equity - Summary of Equity Awards Granted Prior to 2017 Plan and Stock Option Activity (Details) Details 27 false false R28.htm 100270 - Disclosure - Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureConcentrationsSignificantCustomersWithIndividualPercentageOfTotalRevenuesEqualing10OrGreaterDetails Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) Details 28 false false R29.htm 100280 - Disclosure - Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureConcentrationsConcentrationOfAccountsReceivableWithSignificantCustomersRepresenting10OrGreaterOfAccountsReceivableDetails Concentrations - Concentration of Accounts Receivable With Significant Customers Representing 10% or Greater of Accounts Receivable (Details) Details 29 false false R30.htm 100290 - Disclosure - Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureConcentrationsCompanyPrincipalSupplierIsCPMAndProvided10OrGreaterOfCompanyGoodsPurchasedDetails Concentrations - Company Principal Supplier is CPM and Provided 10% or Greater of the Company Goods Purchased (Details) Details 30 false false R31.htm 100300 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureRelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureRelatedPartyTransactions 31 false false R32.htm 100310 - Disclosure - Subsequent Events (Details Narrative) Sheet http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://www.fusemedical.com/20170630/taxonomy/role/DisclosureSubsequentEvents 32 false false All Reports Book All Reports fzmd-20170630.xml fzmd-20170630.xsd fzmd-20170630_cal.xml fzmd-20170630_def.xml fzmd-20170630_lab.xml fzmd-20170630_pre.xml true true ZIP 49 0001564590-17-017201-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-017201-xbrl.zip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
0 MA2.C?!)@^#IVAF1QQLK]M\(!OY.A0O)BADJZ9CSG3$#QXI_D,3I)A-#<@M9Q M$#,X&ZQU!B1'Y:X A/^'3AK.7'!F%(9-^J- 9&91JP[7R=<*#W,?*F&ARQD(P[6*#"' M&#&7E/Y:Q@0<=E&Q2R9!@Y3$C'0 ?'0)?_0PK(BY\(1FBT7&143 N("R_Z+1 MN54<0B(#[]"[N5U;?+_F3!%6Y'P O(2-<"P?88?%2%#QF_7KQL6,T@"$/@.L M_@QNSI:.EA''_)Z*A(_F)@B'HV5W\K1JN?!H'XK\CUJ_W90N4;/6[S:*+E&- M* O>5S0.);>!D*:)UAB*(6B"F#P.&6&VM5+(&^Z.:AU!EV)E&ZM<=Y;0@II#X[VV@M27ZE0 M-:9:A]BP$*WHQ82Q1*QT:;=S3*43J]U?,!13GA"2P/F]!.: J1E8&R9*' MJ>V^@-BZ,= U30+R>;./G]P[YV=PZ&HN1J?=9JO(5( M$G0%'XU$]F7S[2N(@P/T,OK>\]&8#U<;(=NK*_N "8OP(T,G%93XQ'?S->+"A,P"O-KSJ=/E^2RAO@;1W!!6C)H:O@;>(%,>80^@[B #Z7V M-U9=$#)SN::U()73PT\ O8PH+R $@Q>_,(P:#",S 1-%AM*+8OB)S.IPCJB! M'\"$*)0V>PWM%RB2D04$3M .=^A.:7)0V=R'J;)X,\>MQ#:2<>B&?\3I+ %. M!/(E:/R >A Y, P'(/)(8TS3!NA\@[^/_C,YUX(E*SWD]8KE$-( 7U?$83"[ M.R:_A PH#U, #.*=(8/@]A:]615D!NZ=2'E"&$2LLP0\"O*%P*]RIBSF"3'G M'8/03]E%E&)R;E8D+\"3\&43@^ W[U"\Z\\H'!<;W# MI%4$HR',H)J!:4$S0!2.BN&[=JO64"HTX.Z0!UQZ^"HW@$-]UVS66MU>-M*J M](41?(,%0Y\$9Q LON4>!A9Q!)IJ:0B9,1'+L<3R2GTV3.X=46PA[$J^09.2 MB@5#PV$PX=RAEE0RBY9%Y3N&%&0 T@$2"#:B-/ QB39R;T&OXT^@N(%%.5J7 ME.&R$;HT(14><'!.-6R;4N"[Q0#%^.$<DRRR4P=9[,T5IM"!VZ)QPZ].J. MB;._N[-(O'4DZHXA;*#%.9]GQ'N/NR ))?!YP+U=EGB?!8$G#+!@*A$WBO:[ ML"IX*)2B=F7.]VSHHK)##0AJ3VXYSC"VT)E]TK0BVWXJ9L?^RLJ]BS#HA/G>:[#1)$DGO2OMN30V M&@]@.T0Z_!T=/#+#N#V$^!;>A/DIF F8%_QL)%8R<2@VT#X]F.&827.&^R!% MV@%#W&+&F\$;0F"R:I;&(G5E;C[#%RYW4Y;[,:1AMW*" Y+'410$T1U1,)U. M,2VA7!>Q0!^2.D:;0RB'"S0A_B;?T) H<&N IW$,?^ND,$?7"IP5F@M4V-.K(XZ;QA=CAZGL85W4:]W7G0F5$C")+KWT=Z M'X5&2P[5JL*VP3:%;8]/+0 /4 3D:KUXUD.CC7ISRT.C)T=)S)I&HRW2+4>X M]ALJOJB&OGG"7E.5P;_5^4=(+:OS*T_)?Q,,S#]-K7]QRV)WO,T.PQ$N_L,W M%GM;R_X4GSZNA2*W1>YBZK>2UB6IC_OC[ KU3!]/,TF W63Y%=T]9>X*;JE;X M,4=&I^-HSW62K;>J3[KS@IMI+ZK:<&ESN]&I]0>#JE+3WE556 MH;@*XVK.J$LF*3V4I8TU,52AA9:2BE+$FQIJ8RA*D M^N)C34QE*&%EI**4L2;&FIC*$J3ZXF--3&4H866DHI2Q)L::F,H2Y-1/X!W$ M;IGNQ'7?_3);+@;8,7G9,7'FIC*4,+*2$4I8TV,-3&5 M)4CUQ<>:F,I0PLI(12EC38PU,94E2/7%QYJ8RE#"RDA%*6--C#4QE26(/5UV M /ME5U$\8MR>+WMV0E2_.,/JL:I2QKH!MFRFL@2IOOA8$U,92E@9J2AEK(FQ M)J:R!*F^^%@34QE*6!FI*&6LB;$FIK($J;[X6!-3&4I8&:DH9:R)L2:FL@2I M^OFRPN;8MA?UG<0FVH=O,QX_^Y$STPUX*O(WW -M?26IU82>J=;WVO ML'4[JE"F4]VK9JM$IR@D3KOJ5.]O M&J4;H-BJH6&M03P,C6L-8J7)8PWB:9+76L8]D[Q=MY'B(="I,J)I#6.ER6,- MHXT4K3U\0/YTT*X!%-50LM8F'NW!V1.VE>JJ1A?7OZ==XB>H93MA@E6_&FK! MN2FU;]:Y.5CR+GLYCTSAH_=R'KA+_-A5<=;/J:2 6O-8:?)8\UBEV-]:Q4.C M] -VB:U!/$F-:PUBI)IDM=:QLKL$EO#>)*B:0UCIFASK*/>\F\2O$]R8S)[R^>T],%1 R/>[,.MZF!4T/[Q.Q=G8=6=O M;I+(^V,2!4!]\>'/E"?S7Z.$O>?""R*1QNPK /(N@&=^^NM?'.<'_=IE%'H M6^PF/ J_ G_/2%C7Y\<8G?-MK-<_CI/[AM MVV@VFO)#K]UX\1/"JD#]ZU]*48>(:@YF98JA#'>*)8:PT)TE_P&\@[AT^G6G M@"Z1T^2 EU98DA.-G"_LEH4I$S7GPO.B-$P$?.4Q?BOWZ4/?N4EGLX #HVV! M@-[6ZW_.&W"=9,+@_S%C9U-X;B)HG8)_TW\R@-4O5BC0(_"A5Z.W+Z/IS WG MSL3%%\@Z?(_OAH*,__V ZK*5;KIN%&%]B%'!!B*_(_J=#YY MPLM5*D.8RE3EZW18YV$WJ!RW&%G;<2R4M+9C3[:C5PV]96W'\]. ;,?):1)K M$XZ%DJMMPDV6;[$6X7"BB4I:RW%ZSUR2O M$\*3E+'O*TN053'0D1'@ )2?N=6#MD[5/U2+ 2@Y:Y\.EG36/MGPZ9!)LL8\/>>=K'93 M2F]*/?<51U9BJEH)M,DH69N#JVVU[AT361&J6$ST^ 2Q,5%5*'&BHG$ E+'6 M91\1C94@:UR.DP 'H,).5#0.@#+6N!BA2[O>K2RA3E2$K'6Q.LR*QJ%2QEH7 M&[I4F"1[WHRQ)X3VO1G3MMN7U:+,P50(6)N#JVWVZ^>5)=2)BI M4+,ZS(K& MH5+&6A=;7E9ADECC8E68%8U#I8PU+L9F3*=^WV8[5H2L=3E. AR #CM1T3@ MRECK8D.7"I.DHB=C]G1/S9$1*]NAZ51X3W.;1J G*6H'4SFP/PH>NT%KMNOW M;:=X_+U)JT2HYRYHV],M.D=&E0/0B-:>'3+UK#T[M&HY:\ZL.3M4JAR 0K3F M[)"I9\W9;B0]M]'90=#)FK,J4N4 %*(U9X=,/6O.;'1VC*)7T0-.:_;4_"@= M!LQIU4_/RGV-$C<0%=Z6WMAU)1D]=:Q,I$C=8@6H-H#6+E-:8UB$=-7FL0]QTB M=NOWK9^V%M%:1&L1*Z\RK44\:O):BVA#Q).4S2TW%E\G+B M>\KGM_? 3 $1 MW^^R\)5JY,D@> 347R3./].0.>U&S6DUFGW'#7WG/?/8=(@=$YOT;:_F>%'H M <"QF_ H=**1XWI>E(:)<&)XF-\B99P[GDP< 2+%1]R#J1Q/'>S#IV8Q$S " M"(C3;'SO1+$SCIF;P"RK1G.% _\;14$0W8DWSX#O]10W^8\X4\GXCR\:+QR/ M!0%*,2PW^UOI!_I;:1[$*8LS/:.4!,AFX,X$>Z,_O'6D(NDWS+X$SW-XM=>H M=WH/JBD5H>K],UQKQYM0%6*L9[,%ZH,]BM3W"AIT*HW'E8Y?-RR8G7^ ML5#2='A/5N_?MT&:U?M/HDDJ>8> "@:./T61M:BY[\FK2F2'3S*[= "9WU[! M-#^0?,>>U>VTZ_8FCXK1Y+FW-%<21(8PQT^ U!RUCX=+.FL?3JH74=KG@ZC M&Z@-J[*PJO7,R0G2 V**H*)4Y5- Z M,M:Z5*E#BY6@PVC&8D,:>]UT52ES,(DV:W142%/ES=:3%"&[SV-UF!6-0Z6, MM2XYN9KW3YA9$3J,F*9JYUZ.C%KVUK9#IM[!9.!L'^6M35JG/JA*#;=MI%SA MC:$]G>XY,JH<@$:T]NR0J6?MV:'M.EES=L!;4>O"MA/NG;&8DZ_R*Z0\,N0!=&=[?)8D2Z/I='-BDM92[,E2V/:25==& M3VLI3DZ36)MP+)1<;1-N^#=K$0XN=JA<=4]E"'@HEN,$<6[M1.4I:>W$<44. MUDX\1&<]?RWH@SV9B3?'+\[:Q+W3/,V>/W5T+76(EJ+>'!4.0"5 M:2WB49/76L3]GQE\[HR/M8C6(AXJ50Y 95J+>-3DM19QWVG3;F7/#%J+^(B] M9I[@T-0)'ZY_4*N9I^RF9@_6'VQAV+Z-I#U8_RA[BX]=BV-/UN\C;GR"$V$G M; X/0&=:DWC4Y+4FL3I[B]8B6HMH+6+E5::UB$=-7FL1J[.W:"VBM8C6(E9> M95J+>-3DM1:Q.GN+UB)6Q"(>0C]2$YH?7J?B;.RZLS>748@'AF,WX5'XA8L_ MWG/A!9%(8_858'@71-X?/_WU+X[S@W[C"PO,!I/#3%S;Z\<4E?MMH-\_AI_]@LX=&L]&4'WKMQHN?$%H% M[%__4HH\1-5@5J8.RI!GGH+=E8T>P#._1@ES!G5'(2XCL]%$O-AFD2QXXYCQJ;P@'/'DPFUCF6C$0-L6]>D HBQ.7AXX[#7F4<,^9LND05L6P7ZV?PB!U!X$'D*>Z56T.)1<.K-N9,S>F M'K>@_M@=?N"T M&Q+7A"5L.5!@1'" ?.>[)G!LL].@1[YKU\X[\$[,Q$Q2+9C7$),\$1G;F6V/ MXVA*LI!,W,0!&PMOC@)X4S*%%PFB0\QN69@R8C]B4\^3("#\H%T!GSB:2("; MD'8"7P)"2^T.U#.6*K(6$SLOM-NO=0NB"PO) S:<,U1LU'T]*@'C//%#TH,O: M4E'V2#$6Q;3?KS7[@\7Y2146.!-M%9H0X,(4F6WFSJG7=];+O/D6GI8F'O4U MW\BY>A5BPEAR;/SZSS28:R:(HW0\<3Y[282TP"]K!=:(AFB=T50A@P,^P.Z< MD2T.(IA5$A]?^!C>,@$V7:">D$8:3-X8K:T[1;(@WP![-5 AX3/@$4S<<"R- M,3#3E*-1FP/ ":!E".888<5>]9S\%= \,S1]8-*GD@F:@[+?''>$7>V7^*NF M?!2C2?[$#0*8B7B5.N1+OJDYZ0S8PV=3_%+Y'/ ;@U]0*P):$J"=F@A_!&"I M$TN.\Y*_*)H=%ON3P$PWM.FKMI%/!OX^"A3;\=;3BR->@0T,,"&O(L>BA MT:29D]'37@8 AJ]/P :PN-#$'\P">5U>S%#[UHSG')!Z^I-"=Y17@ 8\)5@D M8 9G0^T ).LC!!"S'3*R[90 D$#06R!3& M)(A@!87 66$*& EYIU%O#(C,-&)1VZC1)>]H\=])[TC&/!9)_QSF"VV>UTH$ MNQ $X _7R@@X%YFK"EXN*5N@SMA\N>;\>NDT.VTIAE]^^5@6"\A'0,'^F7*< MJ$N>" K_CAR!^L'-;)3!$!TUG@(BGZJS]ZG:K89TI/)HR,V'A;@:==5[4'9U MYT* L,7P$/P\8K&T*P)=>%*#TNO_KM>I]1I F) EJ/P\QGQ#F0HWT#PMF%[$ M'= +7NQV:^WSYDFY^DC@]7Y-C1R-[(83PAC\A\6W0$%!=!VZWA]G0!(DZ2@- M57@/4>"$HE3I.Y"B'4&\!TJE)F]1F:.N!CT-*'#')!>2[9%&@AX!_5@'^^=@ MYB[7L&7,=CGA;.1\^,:\E'CH,X$C0]>/*)!\JIZY(A@X:%;]3+XXO2K0;V&$ MT,5C\K4*Y@.UXR@;Q/#$_0C5I/:>8&H'5#:?HJ$&CANY/,:49FKRGYKP6)3C MREA]04&.@=Z^1 M&Y,O])YT&_AYI>Y^V>R[F.$!Q$#*^5^*.\C%$%NX_3NY]LZ5NM-H9XWS7:O6 M[ZI(J5<;]/LD/TQK:G*05J!$Y9\F&=V*:UT=XHR!,V(WJ!58XU9ZKQ'EH]BW M&:[S_DF(32GI'1+,Q)5N?D0,[U\'.I,K\ -/_1,E2(7Y(WX M9! *@V9I:Y1ZBN6& 1]+$5_PAB&6PTB04[8>)V.HY\E-RJ=+G&8;W.F;=#H% MNW1!V;\:_,F!:WI]4(F@11/GW_"O24V9QGZOV6AM>;N89B&A:3 MXP?^!>CV9.XH0F:Q'9H@I'D(B]#DQ@UC!S0R\1/2O-OK0H@1XTX0[4(&X+OB MG7_BSIUK\K<@-'*^<'1#?8%>BB)_MS%H:-X$J(;,B)WD4CIZ*2K.'++DCK&P MN(N$>9[U8'RZSCR7UEMT9\&-AP7OU\_YQ&1 2-Z;D.EQ$\X[CLZ<.\<=*)GJ MHB"4\A7D1-!*\ TPVPE2QMS0DJ,/&; ?&>X"?NA-\$#$DM/4K^=*>M-&Y3-* MVLKNUXL!PZ$$$%=GBT622U[22F>GZ!/])MCGT0<5?PG3$3I_C WY7M4WY $? M*!,91K9@J=]3>'@T?WNO93[K?CRHL)DK_6ZM"$HC=IDDQE%1K]'&_,\7%]>@ M:BC?)58JMSQE@1IXZO[!LEA?[2@+D4YGTBN0.WZDHF5*F&%B@_DJ;Y7E]?,8 MH@Q8"$"]!/?< :XT2#"_E@:^XW/,A>D$5R0,0.J& LD^W0!E.1@ES"CF(/.U M((R,'#U%PHYAC=$9)_@P.C//X M-T;X@QC2207#@0(P;>K9PDB9#29%#C2;R2Q2\<$<.MI[ '2A14_<;VJ66F9! MC!R-YP9>&F0S41;S;$A;>>X=&N3Z)D55U$!%[?3!C4/ L;AF\0UFU*ZC@'OS MLKBMWW@,==6L? &1QI#S\E,DQ"L',.40JHY:<:W(H\_2)./$'#%!$3'.RP_7 M-Z^T7 H'F)5[Q-H^#U+4-_![J4YX1T_"KY@%THPOO3M@)>[SXB9% 3I,L\.4 MT91I@)1/*)&#XG++8E"63IB2AX6526IG0&TAI(G>BG/\/$\M;\(NA?=]OAZ= MR)&J>@:Q=D@^("V9,H.H?.](54Y=J1V?*P-SX>N^7[)UVWTV**M00J#G.@%MS#&GMF^W6X,^ID-%- MMF54BC7-6R#:?]!^#Z>,Z39,=)WQ2G%D6@&Q"B8)X(DSR4NW.LQR7O(ZJ]>4 MM:7' =LQ!1H*[=E>*E+/9^I'I$7^TRN%!9)6/]^A6C \!=F]E^H[!+__@DS_ M0AI85]34BEN):.?!1IM.2":!!8YIUMJ-3JT_&-!(N"G8[?>*U"YFATOYY"OM MU$#XF,2I]'R0;KC1@VDBB%D-R5M!NR+A0=0]-Q7231/T_- /#F$*.<7TGC2X3U:O^,J=WJY M-*-9 9'4IX8)'6+TXC'@35]NZ8?2AT8]I[=EY,2X]PI^NSOD <96+S%]](T; MN6\:^Y66G+S>)<*TCL MNEL %91[E JMWT=J1RF;,Y\ MZNPC ?D,9A+&.3V MB4Y^Y3-K8X'U:C@G!EOP:\X.R4WC/B")D# M7@@N)AS,%FBIN4,110X:U3#AP]$0-[#TXBAH GLLI%F$M>;13<*\2NO]:1&E&P _[6(K*DAA*1[,UKX)G8C MC/+0[F?(?;.[R&Z=RUMUH5A/R^@Z<7Z$LW.$N'VNUSRBU*EW.]]O@8%G4V&? MD+&Y .B62#8)H\SX(W^A=Y._8N2F5=5=L6I.L8/A^/$U MQ7/[XH3'VK(K"1<.(%3_:B3L_07ZZ".'^8:!$3?75+1.>PNND/NV],&(Z&MY MT9D,-.2Q@:5*--IC\;PX!1BRPBQR#MTXYM(+GW \-D%*D8Y784)49 FKV2R. MOJEM!^ T6$:^%I'%Z$H/&:3.!T-I; F%?4O-,*85%S!UO,N$R.W1PA14(JI%086!-,J2E\03N6$)^B 2>$1!NSS2/4X(:,R$ MSC$_RU ],1\%/<#D)V;(,$::GK0L9(\KS/!HHE2#TV$SMLLKCK@5DT(FM\FV=DF.<28YIA0*UD$:OUCMO MR], G5:SUFOWD-F1>32_KTJ--)O:,:_)*C[\22NXU0/0&Z9JW.'=TLD+[SOC MF+F)S@NL(N)&;;R5/BVJX*^QZS-XYS/B^D*1\DOF9B_O '6L"M8;E)KQZ\JGDL>/5E=?+ =L>H\T/,M/+JMCY_H #GE4%*:-8]P>!6T>X6:3 M=AREN@XWE989DQ85FE';AGIZPRC8=49MJ0",*/CHVN2_WY%RXN0U2D\-LW.> MCM<<#R@73=%&H7[6U0.@=M4&#A8),MS RC2Q<6R@[ER[\DQ;$E,ULCR-EO.9 M0HE95J$VWX!0\@25+'0 +,\C?1+-E>6"LO..K#6 H#3(#NV25TJ+H%KLC(P^ MUK'CUHJ'-=Z@ 0D&U,U@7&$Z+&K/MNWDM'>3A>)R-"?LV\2E9#I1 &)6\&*% M]+YI7">Z9;%N$*".O9LLI/..=QP@I0$EA9AV8ST>>^D44>+IN@U-E>4RE0[YF)>$'JV>--:XH &1 M3W'S5!7'@;9\.>*Q0-#QS#1^ ME_15OCE#LM3329XY//#./@ID",YQZIL!:" MP0G,.(XBI60V]<4R^E\5E"L&I]@-+-^)R#-;1G4OZ05VBQ'G+=-C%J5V66 Q M@4=I@M(14;VBGRH+$5"#D(K,JJ>,S&1*>3IYF%P6,I!-T9V6?"[ RU0--B2= ME"G"$\<\V>B K9+P13V %6%?W6]K]$#O- MM)&H:JGE+:1ZJ]I"=E>3\C63%/<6'U.N6SC6V1Q=UI75>I#[;GSH?R*$K5R+^6 MZ^:5^R"PP2>ID)JT^"'#$_9N/*\AV!"[I!XK*[#7>3;5KHA$?1K!D '_@]'6 M'[@R*-5TUHM$&TC^7U9>N+D8MI9-N(B*PN:_KI'%YV4J7;I$;#J+8NIDN +I MF6K*/+*5N$?_+,>W3.'AF[,T!JUC$$,SI<*1*%X#MD"W'&56B?. MP/P(%;R2(,J&FH# (2%,9HQDV2E*".7 8NR\+W(>7K?'DN4(XA7@CQT*A>_ MTIQ.T?='>[HD#2L6L$G$_^["HV]A<2HY(:2J\:)Q""3)-\"HRQ@+W4 5XP7Z M>*PA3["H!&.TY42Z\9!*CF^N"(RPJ4U*C*TC$PQZ9ISB7/3N4G6DB3(Z,M:K M.6[J/+L44<,(AGOC:HM4%E[*?1.4)O=.^B? C6X*!B*F@2"\C-, *W^W M\%+*_8_%WL9T\/R+Q"M"NL9=V5]'XT,/6Q3:' -OIZ.E2 "%[EA*BDCVZ .S M(U*7^O\R/-2MVLAA,@?/?ZASD^P;!"C \=2[CTH]F'(TY E .CFAFBU0#0 \ M"$^"9C'+1/)NBGD7AIAAOETFFE_RVU&"/*7C)9[P\#2!P!IO'<-YZ T84*$.Z\DG.@=58E#R^5I=;+IK9IKS;J MCHU:8:$-#1Y!>(?%"H@P4*)$C\^T0W 1^A^IX3IPQ34$F"7'#?;>H.8P=,@- MG2PEM#DFWHXV(KHQCM)ZQH*UY47!437?679DC.?&5(?QQ3YJ\CRN;F*E!O$I MNZAD_<^4"VRHH7I"K3L5ACVKLFYARX=^BYY.=E12E-2JY9"IDGY?-8*3:\G/ MU;T+L'_>C3>)*.LI-]0P88$/3".?!2O\?ZD<]3#%V9=!+T&EKIY'A.,\^;GW MWU-_+(]2YS5;RBVDU$R$AYS0-ZTM8$O#KT_W@6LY<6\Y=J]5)1PCQLF[CU<> M4?\J(^3L_+P^\Y"=KMIVQ3&65@A*K"\[E$/T&K-=@IHS3!.5%3>/Q<-*JW$%@)L=S8+5"$$0F(T!]!X7,EKU,'_*?A-)>R%.\6471A2K_N<>'JZ M272'";M:/IQ0_=)HHDP@F>S?2WQ5CMNTK,=;D];;3$R&4! M=DT"UI()>MJGIW#=1)-<);R.Y<)S!ZL ,"6!AY3D70GZK21*Y/'.?/+,<:'8 M@% DFQ4#Y^-F22E:E^B"J#/.22N$&P=5U$E=9>QPU XE<*C);.5>T*U"DN3+"D@>1OA;LRJ2<*1NHP6$*E2L7F M$QC0S60+HEQ"9%UP;LXT76Q_0ZCL((-8%1-+DF7'J4?C/5]VMP>PS( MEZ/-*>)M11G%U55>@K%#\?0^<7EYK$=Z22S?O1&JBZP7U>$EO9 M-NNEU@VMQMNKBYMWV9_-MZ]DEP*__/7?2$@+[U_<_%9X_=>H3N"<8==DXSD= MW,I;""+=%D%>7Z/WNXV1Z@Z,K$2Y@K-_J-W79ST>&6/*T#%=JK M^(-*;!MF6\Y#?;^SE":8*GET%7$&7L$(,> :^%G@S+R 7F;<97]H>5L0W6LD MK8TPNG(LW'W0[.H:MP^21WWE^'(RW5.LE$ :!^ID;L MHVFE#7;BB@UC:J*=WS& NG\;?:]T>N^LT2KH=&J':"IM[:-F/J!+N^2,Z30[ M.KOJ$@N@$1Z)R3;1Z,TEGBAK)1XD M7M\#6"[O@*U,KI%K#;F^T=A!M-(I@2LRSB^_1C/N.:UVXY5S63BQ00\JBM,+ M5,XV4^BE;V:R*E&W9B!]0=27D1^Z%M@J%MF6]$-6-IEY!Q)T+>34UN)W)3;D M4/BII[DDXWR?+A14+3T4+Q+7 :\A"I94 '%?.H3XRQEB5@VYD&F+*/?A!7(S MWD.XA47/CAHMFEO5*%ZV?3+'E")!-P]F;24IJ:;PA#5+0Y4E6E0?TN3."E]0 M,\-UNJBP/5K>E5+=13%D 6ZQZ^HJ&";SEI==&Q_-ETE&=OI?UO3-9/P'/$F$Q?)D6J)JLX)R9;F5P:,TQSR +,)U:>-37?;) MLKO5\JXXV]T5LK)ESK,=G#>OD:8+IM55W3^^0-JS(,#>ZK# [&]US3?]K2X0 ME[VQL^O"U5W?N"OLS@1[HS^\=>1]X'V /[_5V[CA^@GO)._UZN>#I7O)"S?. MF_>2K[\^OM@;_"'7DC\SVY=Q"7UZIHOCZ[W6@VBT!XHLI7A7'4<;;-,FZ/%I M ^ !0H XK1=/0"?]U;LPB ?1>[,ZM%#DO#'[>L6)U_+)0T(X&3U?N]:N@/J%14H/8XY*E2^[]+>2HMSM,-]Y261R>)--K'3Y$'^TJ/ M3XGG4R@>Y7&H3RB1I5 M_!M^%O>4H\=/:EI_HBJ4L!JMJI21?H-U"W"UW5JC\]P;G%:&#D^&K)VI"B6L MC%25,M;.Y.3JU=K6SE2-*':;M>H4HA-ZDRCPL6H_CFX7+Q^N6!;'>@55H835 M:%6EC/4*3*^@WQI4EE)6AJI*&6MGJD()*R-5I8RU,];.5)HH5=_[W-?1RR,C MV^?1"+NF/K3NMV(G0'=WNZ(W5C-6D7FOKPU/6 \'5-FO=P7VKK_9^ MH&A;/6F%KP+DLI:MFN2QENTXJ6)@M&OM;K>RM+39^ZI2QIJJJE#"FJJ#)9TU53O0L].NG7>LJ:H85>Q&\T&2 M[1,3X@W>!2@OGV'8 'V&U^,M7(AJD_.5(=D!I'=M3\[N1]&6_-AAT MJJ$K;79^+:E>58-*UJ(=FDZT%NV0J6JG9^K*;Y&J.2%[[M[.:UR3$Z;7 22/MT@ M6&S9NU,?3"VO(G>G-NI->W=J.25_C>I.-%IE&XY[[>3T//?E&/;>5*OSCXE: M5N=7GI+_)AB8?YI:_^*6Q>Z8G>;B/WQCLJX:ML?;^^6E ]O[D MM+^UX\="26O'3]:.?V%3EX<@,:>Y_$OX)7:])'6#TT3 5Q9/JV%$*UA47!DJ M68?G@*A@'9[*4_)B/([9V$U.U.A_!*/'0\&]TUS^O]P@K4ST;HW>ODIL*M.W M46W,'W]AXCLW<$./.5&:B,0-$1N.FSCOF<>F0Q8[[295D?0J6[^XRH\Y,CH= M1WWP2=;^5I]TYP4WTW;*VM UNMWHU/H#>RM3Q0A3?3FSQJHRE+#&ZL .JE@; MM0,5&Z!HJDI(:YXJ2QEKGJI""6N>#I5TUD[MTG6XWJXJ':V9JBQEK)FJ"B6L MF;)1U/%:)^S7U[CO!7'60#VC6GS.GOB/O:?8;-?[E2?2S_)H^S/OT%L7HBI% M9U:+'1QEI*M@/0%<[5E5B63%I[*4L2:F*I2P,E)1RE@38TU,90E2??&Q)J8R ME+ R4E'*6!/S_[=WK;UMX]KV>X'Y#T3.G8-S@<35P\].6R"/II-!VP1)YAS, MIT*1Z)BWLN01I:0^O_Z2DA_R0[(D2S8I;6 >CA\2]UKD7MSDUB9(C+"$B#]\ M0&*$80+&B*#,@,2 Q A+2-.?P)-BMVQ>B:OH?AFDW(@B-K#KWUAF8!JP_S0 MAD]CAP](C#!,P!@1E!F0&) 880D1?_B Q C#!(P109D!B0&)$980\8>HRJH^<'9#F6 M%GRBD.P-,I\K#-,.$=)TQ#UJ5B26A!EW(&I"TP.B5DOV0-1 U&#<@:@UDQX0 MM5JR!Z(&H@;C#D2MF?2 J-62/1 U$+5FCKMC/CJ8MA5JN<&3C9'6:I[871BV MX9@8N8%/?T=.>L@99;28.+$S]S)JIKK1/>_V^&/XVN[.% 2H 72"/8M(#\E@%O46/F =5E(UI MA3DV,3PL"*(<'A<$46AZ0!";22\H8\F4ZRV(%&7@29BA"<(H-#T@C! I@A[N ML7[:UT]9*\1PLJ")M7UPML%:.3NJT>#VE[1+?(!1& M6GHW9SD5,US[6N\159\7!/$?( 0KR*#0]((\BQ?Z@BK(QO<4$9A=HE!&!LY-$$8A:8'A!$B1=##8^T2-U(3(S[F=*0Q=]Q- MXK<^WYA MO1U>NH[)VN^%U[D=WA/ZXV+*_WMMF+[K+2Z B/7AY/H[(UKM:R?(9/:PC^[Q M\,/))7]7T=6!HG:_SVZQ=[Q(JJJ-&+KJZ MQF=C]KT1189C(4I^SO_$K*W6ZI9Y^!7VHGL:_IJS;SA3-#+X#Y\=,B0FNQ4R M \JLQAY%K\0?(68TZPQ68-AH@CW.B/&,D3M$ONNS][P(>';#O]E7^//[)A)FMK.,DIS43T4?W%.GES;2M3V?A9MW\\] MAF3^0^TJOS%/M_SC,>8PE^]^XJXRR3?5&RJN#TL@F% L_Q"G%,:$*ZPIC $@G)(Q (HA_!,@G+4*Y8 Y2AK\_303]@FNJ]H+Z3^*2>7 MLUT]I(J:>Y*E[D0CLX4D2 9;S=_;D[ZZYP2U.T=/DDT;A(T<8[\*2TA2#%0S M B1P\CQBV&\=^^%[T"?0 M)[$(D,#)@3Y)2QWH$X1/,E.2(D_'/"04-J7FFU+'/G,'1HRHF4"[1 DTAUNK M:85C(AA"@L5$U1,",9$H3#1T:$C #*A+&1$-C" 0EWH2(($+:^C0D( 9$)=8 MZ**W.L(2U= A!.H"/@R&AJS,@+I Z"(P)25OQL 30F5OQNBP?2D6,])D"(#F M<&O57FL@+%$-'4*0H 8^#(:&K,R ND!ZF<"4@+B "X.A(2LS("ZQS9AVJVBQ M'1A"H"[U)$ "'];0H2$!,Z N$+H(3(F@3\:4=$Y-STE72*3LU8D< C@I[)S![HF6S9RLB*!0P0YDYD]D+-\E X@.I.")Y S$5F1P"&"G,G,'L@91&=U''J"/N"4 MLJ=FN<&3C9'6:I[*/;J^85.!MZ5W5MU,XQ(D4(;LD -27'>-' R.GF.2))*) M3K:1@_/868TI,5^#U5 "EPF*6&MZ01&%B1I!$$$001"%]Y@@B+6F%P2Q[!"Q MTRJ:/PV*"(H(BBB\RP1%K#6]H(@0(C9R;&;<6'SK&PRTQ;+H;F;7F_=N GCT;QN3=@SG"5F!C>CN\=!V3W<\S?.(ZM\-[0G]<3/E_KPW3 M=[U'UJ0+VS5_?/SE#4+O][@ (M:'D^OOC%&UKY\@DQG /KK'PP\GE_Q=15<' MBMK]/KO%RF6CBUY@QQPQR'Z<_R1T_KUSTW0#QZ?WV,3DA9/P%8^?L/==4]2> MHBIJ]**K*RQ/B/W&S8XLC[?3A16*?$MLW] M&S-W\??,_HS/ M"4SENCB38Y&_J;3W7 %'2U XV2Q0&?6'2/B,.M):R7TYUO<<*^/RZ,!F? M\#;6[Q1,C3%6;!0/T7;Q;%>XH^DR;$NGDCU]TD6!/OKDCSGO35 M?;V[K;?@C!/!.#GV9F\B(5$(4W\")'!RH$_24@?Z)-5^+,B3''52(:Q:A%7: MD1&2GJZIV:L2. 10<]D M9@_T3+9=)Y SB;>BTL*V!E< @R,3:DNM-$N04/VKO'J8_5;GR&Q#^2\9MLY2 M@KX&JZ$$+A,4L=;T@B+6;V?7=>B8=#8@'*8 MCR.,+MWQQ'"F(>7_Z&MJ[S>*)AYQ3#(Q;$2#R<0FV$.$HLN[KV&]S(GGOA + M6UL*6_H)%WSFJ*))X)DC@[)?LL:%WYU@CX2?1-4RV2=/V'9?H?JE(-4OMQ[ M>?22:'+,LD0IA*9E/KFX<870KETO!#2A+DPF:\(#^0F*(%WL(%S6DS $RJ(<#<0<=$)X)D$GZA4Y M@$[LX[..GR.[]Z9&S3:F'^9[?"+7G\B;,0*/BDB4%%3LD%QXEB0E*>CX99G% MU4N1F!(C3U:$71N16)' 9X(DUII>D,22.=?9K%\,7PN*"(HH'2L2N$Q0Q%K3 M"XI8_K.4QU[Q 44$1925%0E<)BABK>D%12Q[V;0C[+.4H(@5UN YP$-3#2XZ ML%<)GD-6F8." ](FAI4MDE!PH)*]Q:IS<:#B0!EQXP&>"&NP'$K@,T$2:TTO M2*(X>XN@B*"(H(C"NTQ0Q%K3"XHHSMXB*"(H(BBB\"X3%+'6]((BBK.W"(HH MB"(VN4ZKS]ZZH33 UE7@L8YU%Y;N?!BQGD)9*\./:+PT:V=W:=9[;!L^MNX, MSY\^'YW;=Z[Z1A%2I5I.X\ MU\38HM>>.^:?&PQNCOIX[#KA]>(@=<4%25F!B%"WK:F]/Q^N3CZVUU#::?&^ M7:E7.DKW&#]_Q18Q#?O&L0+J>P33&\=TO8D;C8Q]^E'[X/VH+RA"R9U(U_;J M1'?&=,R\&/-G"VSY+W@1YY6N,R@5F-DO;IP73)FOW ^!;KNK#&( I%@4V T5@/#H=?:"^?UO4S!A(MY.PQ8_NW:SD-.NX=F!A MZ\:)7>+3WP%ALRX.>APB-06BS6K@&=R!JBOM7K\_LRQWV\JR2TNWJSNWJYO5 M+M9].[WN?F;->_^E04>Q#\_]2\/SIHS:?QMV@.-FZ+OHV='Z>)>+^9_T!A1M M;%I]^BQ0E]38ZZN;RQN'!AZVSL=NX/CQ-J9-U/("JG56O?K6FV^V[T^')+4N M;8:TK77)_D53NMV!OMJVM1OG:EG:K"3R?+J:<4*EJ5V]FZ-E7XCQ1&SB3Z]= M[T_F&3W?(,ZC\?/.I20!QR.X>'/3I@A[C)NL3>Y8?$Q.N(I_]EP:<[YLKK-;=Q,O=C%]G$[PZED5XTG@ M8V_QE17ES=KMM($V6)V!I1A3U/ T-S-F!\^@L-YV+B+4XN!^-JIU^YC\NPBE.&U3FX/H35.^8_ M>3C2]4ZGZN;NF/_DF:[I@W;!YIZ;9C .PBCZ"D\\=K-P*86]MC%_P7[.YGN> M3_X;OI]XZ;AA>2=%R8:Q(+6]M*NLME:.@)HVN7;.88;9G 8*KW9NN4ZF.O1 M_X1U8!;WM]08C'F@*0?4#)/%XX.:?9%[ 6J_+%"7EE\:MGV-#>YXX@AFV X4 M#L&/L3,U1\PL](21%>#H0,UHZ)ZB8.(Z#.HQ?W-VFB;[#+-/#)]]HZ873I-/8=]#(H.&?898/\EW>$N[)$$>%WXG9.>%S*G[C MJ''L7X?UN8E!K-C9I!PE,NM/Z,FP^181?\-%T0;%^H&D\\:9X78$HN$>*@=V MU@+>5_GEV578+_]':2E]?D!I=+76:N_>VD=3N_+272]'QAV_F1KOVAGV<47H MVIF761=[11S-1 B3LQU%R8!0BJFK M8,U=;>(42&COF](OQ2@/B7[-& M.,]7K*O&+=^Q][LN5G,_K_5"/Q^+B'?=-+6)WXPQG^?;;.+OD^$PWL"=N[JK M#?S:0O>$B9EGH04W;4N6XF-7VM.AJ9?X2%V+&.U M5^W8XUUO^G5 F:"?LVZ&OF+\ WNGZ#Z@_A2Q/F?[7"S_WK.^:-$64[13=..8NTQ=-#_5U*MH;D8H5Q&F MLS%3=VX5KYK*N\Z9TC[3U,2&K=UL,P"F_ >8!8F??O+?!(2.N$?;5 MVRZ1,KCW\^AM78]+WDY;5DW?VM2U+6A-RS 3+F9SL9RQ:]<;8X\-OVOBC?=< M*="4CK9$+QF.(K!EF&4="K:Y["Q4_?;5P7O/);1.-S]V83;BA4&QQ6?,F+4Z M%#_/XR%#M$*T_,HL6^W\E;G@*(TQ2F^\<:+4QCC<&:9=X776UY_"C*%X6_C* MT"K2_!WNVY;3X%?6JND#?F'_PSC^BT*I6_$#/X[5O01@ M+M'7\RZ.[\QBJZS5!P1E9XY?WM0^24#Y])/%B(1RE[4)RLY)XK% V6AU93WE M/^&C)-@Z9Y&5\8QG-\9A,!J':L=T=6-0:;OC8TVKI!>E671T&'=.G==Z7!-@ MC'7VK##FS> \,(P9+=H"X]/NFS[EYNX>C]ED MG2Z3I<.1_O&N_9?^5>U?K8%VV/8+!>#.[)#54/%._VM0,P"3NWU2 ^)+P?K. M?-VJ 2S0_LH$Y8;=A\7/Q%S+L-?T'=DO^7(_E#+F^[M:?WB0VCMB@%SKLOK1 M4"JG+Z_>)C[DVGFC@IPP5=+^C?R(Y<.]_*'>V9X0&[0KEF9(H-FXU,7T COF M:&QX/U:B=,/&])X'W '^AOW5^'S+139RV0/JNV/L;7QU]4I?C?]SO?EWZ2+> MG[^CQJ/\=D*4KV_=N6YW^BMI%8D %H,Z0TZ.M%!WYU!O/,BT'>KU#):2HVBQ79Q M7ZT,*NW5M8L6V\+Z:HFBQ0+>=S"H%#R)XC_A_&E7HHBN@(<<=-I5@B=1C":< MS^N6&'7-LY7OL8G)RV;"2U8Z=K\N,>X2 M!.M]EGZ52OMUB8&7>%@+UJ]+C+P$P7J?93*ERM"K6V+H)1[6>?NU6JT/*3'V M$@3K/984U':5R4+=$D,U\; 6RU_W2HSL*L>Z2&C7KW)3N5=B:'<(],3RJ;T2 M8SM>^_YV^-EU+?KH^H:=&[N'8#+A961VC/-E&F]XKW/'^N8Z>#RQW2G&#]A[ M(2:FC\NG72^F\PLO?,+\C4S)FML+#:E5>X42(T&YF553 M2XP"#]/W*O5\X?%"5X2?0/84^*YW_NSA\)FI3\,A9@[Z!:]5N^J7>\A5&,W> M?9T=AL;:2P/;-UB\\N7+97*]1_9*.U/Z9XHV.R!IIP4[K.4/6,:-S!" 56[D MG?I7BG6\Q:L#('9;@FE4A(:?#\7[:+C!%S4A5OX9K-5X'I4?+"H" M8.4?R5J58^JK\;+\QT.LW/*\5;JM$KO86B'!51^X6<.VY -FJOOP\>\=,=UKYN&Y22(<'6%E@RS)X%K"2>_?R+'+"4@F>& MF??Q\%X%^-'=.4J+3],7.++&>:YMA\?IL 8YSY]F2[91\53_W!H3 MAX>AX5+"N6/-+OA[,#:<2V-"?,.>K^[N5>;V?'Q!W ??& Y9(XHZRGZW&R_W MG@AB$;"+S_]E CM'9R^ ]/PX]FO7N\8KX57JD<3U@;=(N*+U.O'#P%8AS(QO M\5!#+GP+G+76[V7%=W8LP3W[PA8/D2$X>0B>*/X[X*N4O)CRYKKPRL=QNWK\ MH(U,)=)7%&BSQ;$5T? 8U,M9N;D+_$P<9_.8@]3SH4LPJ[^TCZ_O]LZ4WAD_ M'&%'"Y/,^!26/5NU0<]R4G2I-JC:&7_X,ZUYS(#W;W\^>?;'_P=02P,$% M @ E',*2V2%12Q"# /&X !$ !F>FUD+3(P,3EI/J]42X%S_]&I;Z)EP01UVT^B M-#S1Q,*@M/'3CW_]R_5WS28:W,U0SY#TF0RH,"Q'>)R7MQUVNW!X.ZNV89_WER)=&)\;V&#$/!&+$L MLD9WH=,_H/&X?XIZEH6F2EB@*5'C0,S3P);PAQ&88>**@07/OFG$1O+UB5NG M#E^V3,E;-)P6I_ MZ+9#!B9#9G?AM2J6;[$5)F5M*ROFS=ONBY3?&1FJ)L9LY4*HA8YQ,0K/Q M0(,2/T^#H=GT 9XN>"$D1!,)Y0W'8Y*OL[L(&C-0691]S>E%-3]A$?7RFI)_ MZ6KISN7E94NW1H \SB&/[$(4M&9 (J_&*EM)M61%(#5V!" U$L&$I>3TR9/D MSN'V@"RP9P'='OO#PQ9=4&)"YK.(REL)@5BSQ'Q)Y .VB7"Q0:K$9-:HP1AW M6K_=C_VLV8"9C] UM5V'2^2G@+%CZ%28PY&Z:X;AT%2/FITS\/?T50!BEHEU M5RRUO@%"&"M[0=@$VEX0POFI^K[8U6OVA"[5GU;-G.0M8DD1/FEN@G,7B-Q, M41[+=O)0%\U-%LD=@EV)YU CH5>*BD.17EVJQ\'VLJ:"X5(%8N=#J4!,+XO? M@L%A#]\*([ZD5P^->-(/;TJP4KAP[($DGNRCN\I8LI:,ZF"B141?50616H*J M XC5'\%UO8?U MJ;ZJW/]V=1L P(PY4O>J[]43UZ5LX02W\$ M=E?U:L-D9 MZP)*-?T\'96J+EI*N)74KU;:1;A"9":![1G5'JB]#FRLXONYL"ND^KIN;6ML M&P/8YH3]J*]=#ML@;=0)-5!DCQ-^M:@ M!"!#"Y)*9:*_$=*,B1\0MJ)NU#ISTQ P:2SREEN"UOL,*K!?=5"3 9,]IH-( MIG!(W\EQ"S]5=1Q4B+7;Y[%J/E9W(;%4=7<[%V5[_1B3JNQ\E.$KY7.)7QWF MV&L?9IAXP__WF#ED &X]@A6%VQI80R\A4Q#_O91X7L+O9&3\Z!(S$_GF4,Q> MM35@[TR^_^+Q[6O (9B< 71]MM"?/ R&#[/AX+8W[CWTA[,OP^%\%B.Q2+*( MOX[B+S("UY$=%!A"OJ6:N4,P]XAA6R)71"H[Y6E,JA5Q>E:64W22,/Q]S?&> M',_FO?GP?O@PGTWN)H_#:6\^FCS,?F;8,ZE49X$Y1!?I%K'=WAA-I_T__5E,AX,I[/AOW\>S?]3FOL\&T4Q<%XV M!H).T.@!Q;OY.W8=\4_D]U9'Q"$BHC?[>_+I'$LA0+>+_HC3_8!MIXW4. MJ%Y?1Y]A/V )_YTL)K#QT.Z(>%V=)U;$Y ==3T<6X,8W@IP%VIBI":M(V(PN M&5V /&QS#'U03=GRT;&H =O&3.[R-8IH_)BB,68/;0RBT&+-:$5&'_U=_UKM M6O_PJ*L27R:1F8)%_'U*\1>:\3>VH:&:MJJ9TY%$/.(U?K+(E*BS81/V('+7 M+,P1+Z+P,IU)E3$46(/[P" *+-9<5N2R[]@VE6H:")ADXF[-5<5ET@I6-\73F62;A0V4VNLU?%M%@1SHN1">3;J)DZY#9O_^U>V6U? MYZ+JM@^=A%?U(S>(3GR#-9??7G[F,+E3N(C' MC%.97:5H3>5A:M(<&C,%BRA,'\PDS=2\'>Y,>T DII9XP%P]>"8ES[A3:D6< M9IS49)QYHY/ ,(HLUR0?M$ JQ73A7_;>\'<%)\Y%,J0Q3EU^-Q15A\MS&!N:_V)JQS2;^#8<%XR0@[675%D MI4_7=D>6.B37L-3>,'CF(T,!-*2Q(>GX;]10\'0NTC:1CQ"%$.NB\T#'/+%= M6]\3TK&!N5^I7(V8"0-M>MAZ)%S)XR69+.:.Q-:4/!/F$15M&/ M.^T)_ZQ> MYD)X7J#^&?T616SZ'''K$"JYC8V0H1> AC;8T :@^=)]%,9P^5,Z(86T?1:A0" M1 M@0"8+AQ":!E1*E6"^.FF3Z9W?Z.FWO"\P;=L MRFULBY2*:,[X=N+VMW#^S]B];L7?00)WR7>47 =O/=-LJ%_6_Y[W^_'>DX"$ M:TC_#2DWC7*R_D_E]5OMKN 9E @C26R%L8$$T .*GM+XS!W/#04IB#20?^T2 MV 2:BILH' M4:N %0N+U9WEO(CHMU7; W 86T27# MYV_LW@);(C< TL=G4-%2F6:W4/#8J$M]? ]3\[,#L'2YQ%,SN(+"L;FJ@F_N M1&]6W4RVE(\E)(_,N9V1YW\=IG2@;HL?F9O)&CY8E[>=*Q Z,I=@?V$08HH[ M[M@C(3SUEZ4=#:3W<-*45RMHYX;WI(?J MC=SM=\Z[=]BFUOH+)"$ )L;4ID$YP" IK:A[3^PGPB.?JZ@DB@C3L3%E[TKO ME)#EO;\9&C'34UP0,6*&PUW'MYUTMKS\L7GJ?\ "BV=X$@*H+<\DYHC%\I): M*\P[)7>MTR<$Q89!3=.H0]J?]W@2"_1(?# MQ8+QE*-.3-^WX,L"/"?S;ZDSDWBQ@-4IY1+'E7$22(?,S',DWOQ^7ERW_#^O\./_ %!+ P04 " "4 TV:&$QC(Z>U;1[&7H#FVQ)7D)/2OO[+Y89S8QC(8 MHK1Y(8=(J_U6J]5*W]KG\I<7WS.>@'%,R56M6;=J!A"'NI@\7M4";B+N8%S[ MY>?O_G7Y;],T>C=CH^,(_ 0]S!V/\H#!#^,O/QI_7(_Z1A^3;P^(@]&C3N # M$89I3(68730:S\_/=7?"'5IWJ-^88(*(@Y%G,$QS-4B7 1)2'Z.' M!!C1SX71LIKGIO79M-KWS=,+JW71/*VW6B>?S]HG_[&L"\O:$/#[ H^Q\2,% MU#_5V_761K,AQO->I_L3]?=D\_6];5]WNV-$Z^>35=MFXX\O_;$S!1^9F' A58E[A6+2^C7;[78C^JMLRO$%C_KWJ1/- M3P&]C,P6X;_,53,S_,ILMLR39OV%NS5I \.X9-2#$4R,2($+,9_!58UC?^:% MBD??31E,KFJ3OWS7#(UMG9U88?_O[T&VDL[3CS0/Y7P=W2;4G00N._W.7=<>_V;; M]^-ML$92QI\%923-M80@U7,"+YJ\$%JB*;P(("ZX*P&APE5@C#21NGC42I+#SV %T6^XN(:U4*Z)4]R&,KF=Z"D>[)? MQ4IV'(<&1/ 1.("?T(,'(D+8,[3@+ MPXOB:LB74_7J*!M_#AMI%J.IZW< #YZ -($["K<5^8G+A)8<(16K?T<%\"&: MA^%L!&%BX0X1$QAXUT.EM5! 6M7Y M:3R6>BKZIF_EB=MR]973-[5[Q2I'0TVIYP+C87XHYBH:I_4^@$-@X4>'"GG, MH$3(I0;$D5%#U3KN M%$/^] $AOTT@8KRG'Q!OD7POML#9![1 D10^ML"Y5A9(2SO2][3U\2N&^ODC M0@V[J"?GWZIMOO-]:H)>X/CSKCJ5J67CS69D8ZQZ MY63I+.GF$:08G1[CURM1VXH_OS@BAJU7JK85=K*090VSI5=NMA5FH5JC&'W) MK.RR\:H(K,+BMO%]Y][^8M_=CP.HU@VM=&O8B5_ M19CT*><#,I8[XV"2R(C6Z9"*^D4E5@PL"H2_ @&&/!D7.ZZ/">:"H; 0?1DO M56 5DUOMF] MZEH]$.64?=7QJ+EF.@BZQ;*Z8N@5)$K:D#[ (A3%>6-B^PT(S=1U=Z MMB#6E)2@%$'['EP[.S>BJEFVT'=ZSY6B<-7')8,4!EEU;LC"]/]+&A M[A7<$> LV9?5NDAE87;#6&R$@P-?L6L[.VA"T-'<,>9&]^.1F_+^N;_\AX[0 MA0S:^SUF98_W.P NOY%'A91)W:SC40&A)+;ZF0@K5J0"3UBFW=?SKQS<1;CD MX;*,WJ>TJ%6+'B$)Y'?+HEP&E3$#W-\.ZF%KJ3, M_@V3=8NM5WWV_NVBSG$H$#WO@>.HQF2%B5_-&*']6ZO8V;\4K?1W,5CBZJ<4 M/_5WL52Q2\#=R:\/;,(W=\6Z/JEX!&.]9@UT?=;Q0*9[0RCI^D#D(>SUAE+4 M]2'*0QIK32>7>B#S0/4.\;O>5\GWYNFV%[XFPEOCSBUR4))TM,J&8EI6_O+& M^&4;\ZZ7 48V1(E&0*^ECO=WX&-&T M$,0BSW$O9T37FUM5.^QO,>Y>X9ZVM5RN_Y.'G_\/4$L#!!0 ( )1S"DNG M*:Z>/14 )M6 0 5 9GIM9"TR,#$W,#8S,%]D968N>&UL[5U;<]LZDG[? MJOT/6L_+3.W*DGQ)XE0R4[8L):J5+:_DLSO[=(HF(1L;DM I&W-KU^ I$3) MX@4-"KSH* ^)(XN-_IJX-/IK-+[][=VQ6Z^(,DS<[R>]T^Y)"[DFL;#[_/W$ M9VV#F1B?_.VO__HOW_ZMW6[=#F>M:]/#K^@6,],FS*?HS[.[O[3^?C,=M\;8 M_?5D,-2Z):;O(-=KM5LOGK?XVNF\O;V=6G-FDE.3.)TY=@W7Q(;=9HB^8A.Q M3JO=7C72I\CPN#ZM6\-#K>#/U]99M_>YW?W2[EX]]BZ_=L^^]BY/S\[.OWRZ M.O_W;O=KM[LAX+]#/*V-/US Z<7IU>G9QM<>#/.7\8Q:H]N-K]U>#"YN^N=? MNCQUN[>WPV&[R_^<]ZZZO4_\Q][G[N=-S$*]'^TQN/^:>O:MEM3\676FB)A!V2=1K+LE2'Y MVW'9]Y,-([X_4?N4T.?.&5>CL_KB2?C-K^\,;WW[[7SUW5[G[W?CF?F"'*.- M7>9Q5>*GA)BDYWI75U>=X+?KK_+F+6_]W4UM+COA+_E7&?[*@J;&Q Q>I02$ M5NHWQ/_:JZ^UQ4?MWEG[O'?ZSJP3;JY6ZYM!34IL-$7S5J#N5V^Y0-]/&'86 MMH 9?/9"T3Q5D97V0OZED/PGP[9/6I'@WZ:C7X?9Y-A_^?U_8_!;'0_>YST__/G9'P[F,X&__7;Z/%_\P!/N?3?"TO?-G$$ MFP]+[&(Q70IK;'T3O7O(M9"U>EY@+-,)V8%K MDO1@1Z^:LQ>#(C9BS(]?A8R6V\_I5M(CYJ\78EO<"QK\P\?>$J1JPM.:%9XB MCT^BR!H8U.5^)[N+9E-YI=,D:%;\VK*"X6K8#P:V1F[?6&#/L.'ZYPC2#*-/ M'(>XP8N'JY[PL&9UPU[)VUT0E\]DMY&#(*]RBH!&JOW[60GS2;1F?%" 7;]C MT%R=(Z@L&(_&4^S7@/2.GBQ+4>X%H!'_4M!<6$\H[R_81W(K&)+O)-I EMPC8R$VOFK$$DIK<8]&4=0&_-VSHP;R+^7!WB[9UM$MSL M%8UD^@@QQ*N#@)CCP:WA]LX/ FZ:PQWCK'"LYN.47:!VMT(QP"\' '!K6[J& M=M9M/K0/<8$UMG-I;-\ZV_&8O86F8N:D3UR3 Z%!B)P%3L$:3&;\24Y$54&F M'.TT>\_F"[)\WLYDOM7Z9#[%[-?-4OP]-$SN0#]RO#=S1%)L*OHGC>IAF\%TS1*W)]Q&<; MN.8I K1WEHU>&_19Y)HOCD%_P2,2^;(."$P)D99=%99K):#!EGQ998,!QUW2 M))2MN%(<)DM*V?$8"40DW^R''Y_)Z;)9-MH970T*U4A/.YD&V)TMFQ.XT6&! MQH1QI!=1DNN[-"2JHX(XW<]L2,Q#!73:OB .%4@L!36"G!T-4=G:Q9:0GN9+ M""S<&Q[_>S*?$4OW'O?BH"=S>X-*CYXSU;/;K\5 MG_S.[6$B9+$AGPU$=%/DNHI!O68AN'S>/^9S1+E!Q"0GI9VZ;,UV?C"6PJOF M$U>@P4HM:6!R3 MJ!G8R'U%C&L)#WA]?!(ZK*<(/=^%*\'(M7SF43ZQB7F"+D@XI#>BZB[ 4O@-J"9&I/V1-)NT'#2WBH+>GI MABE<0C1PL]%':KB,^YYBV>:>Z,9OH'%!B%1PK]_QO*Y=ZP<)UD$^ 5-7.@0( M$K=W-4$!/[#(LJ)_JE@)T/R'&Q=4Z=1$;:@U*%RH,"^E&*6)H<)]HV],F#!C M!24J'DI#8H42L.7=R(:D@65C3G/G8W"U[,<%ED/H#BP."IX=J"4D]M<*D=&F M&2$S7**0YELC\ M78AQ'K$(0.9$0E+UE$F6DMJCOD'+#[;A>IO-\WX%#/AFR-&?Q^@[?N SW:(% M128.>C?_V4;!*':M:X=0#_\S^#Q55V#>XY[:U!_73V[Y!P6R0GF2- /A:QDV MT;I1>/P[18!FMN-#R2+B7NX""5P!:D:G&S%'I :0(I<;HI MU"@A9S)/-S'X++>TS*K>%XA\@$@K.^L8@# A"RO_!<4!1(E@6J-X!^4!0( # M.#;AISJ$W;-8!\C$F.&[USF95A)WE M]C:$CU!$GKEE:4C6MB+TE*UFS2F:8IY#7GB@(>?;U<#O+QRT-M/% 9HI.TP8 M0Z]3,G]&<%8UG1\BLM;1Z;)2^G_P[B@8G8DK3CY]\,>5XK>R$DO,NDY01#4Z M#1);U4Z;][ %8<9'(D9QI[TA33.@S0D>HOKV<\>8;=VBA,<8X3%&>(P1:HH1 M'EIN<@4QPEID)E<>&FOFSGD/,:*&!@4S9Y)MER@.CU08#B]]Z[OAN-8\9[.P M >3W)#7/5"QF"=F]IT(HJ(SB!L1#[,%8BE5M(U,=H\)%#L""JX^- '36?2S8 M0WS5\")=^CZEP)A!F@3MYYG#9@?O"^YC;!H1=&]&IACM 8$G;^0R[I &5[L0 M]Y6/9LQM>(-K'-IM0_(SY*A'J$PZ4*1\?D[GX!(I(7J[^2H&K_K$Y#RO,?7F2 M2BK$&C4KR"+3Y-M;:XR-)VP'Z?OJI5EEI&H&>&/8XH#*[ 4A;QS=20B/X65) M:3B $C(4DQJ'AAS3932_ZDD]"UT M.\)5@H0CLZ1H#J:*G#$FDL80F[A)>D!P2 C3716)-Q[WA^5MZ*1@)L(JA@W! MDB>I7" B?"1,..9(.!$@)Y'VB&P8<&>DRH%-CAI,+NV\E7] >5=O==!50 M;US1[2H@?$3:S(=+UL,Z+)$9+@TB[W/GC1S :37+ZLZ8[ ]W8TA]R=4NG3EI M%*>O/*S5V/U:#/1JV/UZ%^Z2N"PG<3,6PZLU$RB7O)"RXZUY@H:2/R,?IJCY MR>)]HM^)-\78:WFL?/_8-X*&,?9:DJ#[Q+X3^6W"#4"JV"4B^+7(Z-$$/XN( M4;A9]FV# MR3,D4F)TUYL0344-@_B3' %E'V;,QI%8Z#'!V(?+DD"Z+$D;3@WB11+GCP1@ M3>0^8-@:PV^DK$XD?WUO!*&A. (_^%5Q6+O" )#<$$QV)8E^%[D6E^](C>1* M3-28.WJT;N&(Y-Z^(9?ZR/L_^XW>*)R/+N7,@BO.M$8L.]DF)/(3MZ9_P?H:NFX=&=#"&-5K^$.-56JPP:K4IZ6G?, MRK 1B^;7>Z1P:WB* /UU4;:+*?B]JAPDRQ30>0@F3:D*?5J&D,L64_AZ@K$":A+(55V,%,J24 M3@WD(R+Y9C]\:B"GRV;9J,:7.V5%*&7FFA9-S:U3!,<.=8CQWKD6)O.L3:.HMR=D-0K:^W*.!*5 M?U2BDO)5U]L'39DMJ/$,WY'?._)[1W[OR.\U@M\[TEQ%:*[LE>Q(&'8,W^QL#&B M(]9_N!.G)REYQ1:RMAB#Z*$?A%CLP:?FBS@KN!]^1Y,V]6-Q]@WTC\C5K*P& M)1!VGBNM%E7P[OC[O2N)U?4D>TYLCU' MMN?(]AS9GOI%PH]LS_;YCKRU[,CW].H>#]?,]]2\R)4"WY.V.:C#]3<:^GK1 MS5Y,@M6^ON">=M %C+<;-*@%<2HUD=3->O7@7T%5"0O%L$A:+#(V0[/FXGT0 M)?(W^I1 E*1=N5;PDA.HV.JI"VF--9>$#XM1LB&A0X1@5>$_/JIYVWWKHT>R M83:,6-^G--PM2FN=)05*E3Q08B)DL2$?Q**&I\''8\ H.7R&$D5#[Q%WDR;S M.:+8?19.D_PMNDJR==\?$+WQJ"3J2BUI8')R=(/(,RP(2;ZP,J[B"0O(WOJB M*X1%9,/"LO?H+?@5C-J0E*C[@!#QT.J2U0_C593EQ7.,+(7Q#Q*K>T9#3][( M91[UQ7#@R_DKXIIPQ<(?A;OY0+GG V*# 4++A6?8]A 9'E_["L#9%%*"^K'- M)A0_8^XKA?IXB(\%;QK>)!C'O?=/8J? M?-[H]3-% 6'QB*@C[=*E"]B'*@/N"IIBQQ!>Y%M IP^2P%ZQL>1['3MPC?B" MZCX/HGU\>.&R=VTY?)O%HGTKW^I'[^JG[QANWUA@S[!76WY@#I*.IJL9XG V M.D?00< H(84HI7THL9XI!CJBKIT;3&:>,9_S+CT>]X&C(NUQJ!I3A)[OPAC' MR+5\,7$@-G)-0A0%0E6][_&@^WE3V);'#<;8P=';\3EKM<+ M7@"U!#O06^6S)-3ZN9$ M[0+'=!FE*@^=FY*>!I<9>;B+1B[W^YEO>P;WE>%34YZ8$B?[8DM5M]UE_Y1?YOCZM++I-$E7BD*>D^'GX-6 M;(00M5'?G(PUA1DRQ28-RUO+6,N(Y&K;J%2UO8V#)'>H.;4*,ES!5(R)UU;6 MNRI!KKM.9/<5#S+6G=B"=CR(9$8JS NI0%!/58 9>O&=J@P:*?'#K(YV6L37!R<8R"1:A^CKW5)0R7T MF4&D-^]/!K0([)\UBK'4J CGSGQCZAR^V MYZ]"W8)G&F7%57^6,5=38'+1&/&='O=S/,H[Q\ 5P7]04G/J\] LIRU!-XA[ MX&XA73Z(T'\D@G*'82K\1Z4#$#M/:R\QMM6/5 J+)0HH5VVU8F(90AJM?AE5 M'W?;!I=S3!-1LNK@;+;$Y\M5>G?IABL^KBXY+1<-R3/W'R#G+*N;9MBGKA7/ M,BO@Y,PFV7 3^,INA7LRN:HU>T#5??P#X M4B +( $0(%":]<5M:Z2JS.3S9";QFOFG__BZ1. %9GF"TS^_.7Y[] ; =([C M)'WZ\YMU?ACE\R1Y _(B2N,(X13^^??GR MY6V\R.?X[1POWRV2-$KG280.O_#\>_?OG__X?OO/GWX/T='/QP=<0+^5CX@X/Y' M!+S]^/;3V_??SPY_?#]TD?]]./YT=/P=^?'X#T=_X"W'JTV6/#T7X)OYM\QD D6: M0H3@!ES4#WT KJY.WX(90N".?C@'=Y#B ..WE2Q4 TGH2O,_O^% _/J8H;WKWGICQKO[@F_*3/]#_UOCXUYW/?_G /GW\Z=.G=^ROS4?S1/1!(O;XW7]^ MOKJ?/\-E=)BDU'7F5$&>_)"S7U[A.:-3P2X@_03]K\/Z8X?T5X?'[P\_'+_] MFL=O"&0 _"G#"-[!!:#__GQW*57WZ1W]Q+L4/A'WBJ^B1XB(N53V#\\97(B_ MA[*L]35JPB=JPO%WU(1_$TDK-BL2/WFR7"$"R+LQ5E[#PJZA78$6;;V%68+C M\]0RM&*QUNV^+Z+,,M8RP19M?R 9#]JU>E>D37MQ$2'+]NZ(M&.O@3,4NR8J M,(_H)^@KM/H0%=:3,YFN*D-S0N'7 J8QK)(B%8OG(MN9L!S.WS[AEWD=LZ5E]2R;MW1'V;Q62WXQ>2=SA,6_EC26R!#FNP]'C&KZFW_48[=9&I=2+],%SI;L%3Y[S(F">:%" MO88P+5=0EFO'->)*$Q/]YL=F9$LT@\I5.-T^G$2?-:R-8L@,E9 ,,0-^J;7^ MORY)UA+D'7Q*J(ZTN(Z64"\_=K]KF![;8IQEQZT:0/7XS8T2V/$0+@%!C'31 M]?N^1'JO2@L!5D?W [%9-;#:W]%FF_^Z_4!JTA45[RM^A*ABV>,'@& WUXO ML^AMS9R3KD3INEWGR\;HM>0X=,12#WEUQFSAS;=/BK''@]B$A'/770<@MN"Y M,Z(GIKHN4/2DZK&=+VDCV/J^?0]MQ ,JWY=?BI'%4@1"0!&I &C!ZT[7648- M3_)YA/XOC#+-E"G_OC:*,E'VW;+2!$I5@.KRGCP'B< J* 4&.M+'V]J4[N\0 MH;^F^$MZ#Z,T"(X0Q$(L^^BU_F]4PZ E3IX:]4*ZC5@E*O MW]G?$$-8&;D0V6C/M*@J\%<5#JP%P-\P6J=%E&TN$D0\0\_Q=[YL"'%'CEM' M;Y0!ILVO=\O@QX/PA 1UVXL[ .?.?+=Z8]S!%G",AFFVQ=" M<0X=^G?1"N=_I$<,*HV@5 DJ2SQO:_0SA%6A"Y"-SAI9-7CITN#,]UEHG9*A MT1/.-+?J.E\UQ+8EQ=E"--,":C5^G5D,.1X )1QXD0:R]G(T7BYQ>E_@^:_W MSQ$Q^V9=L.-G)$8T,W6O)-,,T2/4W=XS4PJ8U@-0Z@6<8L\Y6X4QK =BL.P@ M*3$*O%A7ZX07YG?(HID> \4KICBR'J]+5;+]:.67:?*],R[G 2CB% MAGMWE5H!35=S1O@U]_61Z#:2W/LT6\$*R*-W.1#Z
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end